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Executive summary 
 
Background 
Biological therapies are the newest group of drugs to be used in inflammatory bowel disease (IBD). Most 
of these drugs work by targeting a protein in the body called tumour necrosis factor alpha (TNFα). 
Overproduction of this protein is thought to be partly responsible for the chronic inflammation in 
patients with IBD.  
 
The purpose of this audit is to measure the efficacy, safety and appropriate use of the biological 
therapies infliximab and adalimumab, also known as anti-TNFα drugs, in patients with IBD in the UK. The 
audit also aims to capture patients’ views on their quality of life at intervals during their treatment.  
 
This is the fourth report of the biological therapy element of the UK IBD audit; all analyses within this 
report include only those patients who were newly started on biological therapies between 
12 September 2011 (the start of data collection) and 28 February 2015. The data contained within this 
report have only been taken from completed submissions within the biological therapy audit web tool 
(www.ibdbiologicsaudit.org). 
 
The biological therapies audit provides IBD teams with the means to meet Standard A6 of the IBD 
standards;1 specifically, regular review of patient outcomes and auditing of biological therapy. 
Participation in the audit provides the opportunity to review compliance with National Institute for 
Health and Care Excellence (NICE) recommendations technology appraisal 1872 and technology 
appraisal 3293 and also fulfils NICE quality statement 4: monitoring drug treatment in quality 
standard 81.4  
 
Key messages 
Participation in the biological therapies audit has improved substantially over time. Of 159 adult trusts / 
health boards eligible to participate in this audit, 152 (96%) are participating in either the audit or the 
Personalised Anti-TNF Therapy in Crohn’s disease study (PANTs).5 A total of 4718 adult patients have 
now been included in this national analysis. This is a clear demonstration of the effectiveness of 
collaboration between national audit and research, which results in a reduced burden of data entry for 
clinicians and greater engagement.  
 
At some sites, data from only a minority of cases are being entered. The organisational audit in 2013 
collected data on the number of patients newly started on biological therapies. Although 40% of sites 
estimated this figure, when current data are compared with this, it appears possible that only 22% of 
eligible new starters have been audited.  
 
The data presented in this report demonstrate that biological therapies for IBD are effective and 
relatively safe treatments. Patterns of use are changing, with earlier use in patients with less severe 
disease. It is likely that this reflects more appropriate prescribing as physicians become more familiar 
with these drugs. It is also clear that only a minority of patients have their treatment stopped when 
effective, as recommended in the NICE guidance. Further audit will clarify this issue, identifying those 
patients in whom treatment can be stopped. These data are vital for local quality improvement. 
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  HBI 
Key findings 
 
Clinical findings 
 
 
of audited adult patients were being treated with biological therapies within 2 years of being 
diagnosed with Crohn’s disease (CD). (Section 5, p 35) 
 
 
Response to treatment is not related to duration 
of disease: the response rate was 79% in patients 
treated within 1 year of diagnosis and 81% in 
those treated 6–10 years from diagnosis.  
(Section 2, p 21) 
  
 
 
 
Response to 
treatment 
 
Remission 
achieved 
Treatment of CD with a biological 
therapy is effective: 80% of adult patients 
audited experienced a response, with 
remission in 68%. (Section 2, p 21) 
 
Quality of life also improved after 
treatment, with a 61% reduction in 
median Crohn's and ulcerative colitis 
questionnaire (CUCQ)-12 scores.  
(Section 2, p 28) 
 
    
Over the last three rounds of audit, pre-treatment Harvey–Bradshaw 
index (HBI) has fallen from 9 to 7. (Section 2, p 22)   
 
   
Use of concomitant immunosuppression therapy 
has also fallen from 58% to 34%, which suggests 
earlier use of biological therapies in patients with 
milder disease. (Section 2, p 22) 
 
 
 
of patients reported an adverse event when assessed at 3-month follow-up. Infection was 
seen in 2% of patients and mortality in 0.1%; no malignancies were reported.  
(Section 2, p 25) 
 
 
 
Treatment was stopped in   of patients with CD who were followed up at 12 months.  
 
 
The audit data suggest that the treatment was discontinued because it was effective in 34% of these 
patients, while another 23% stopped treatment after experiencing side effects / an adverse event. 
(Section 5, p 43) 
 
9 
 
7 
 
34% 
 
58% 
 
  Immunosuppression 
8% 
 
41% 
9% 
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Participation findings 
 
The number of sites engaging with the biological therapy audit since its inception has been gradually 
increasing:  
from     
 
to 
 
of adult trusts participating in the UK. (Section 6, p 64) 
 
Although participation in the audit has improved over time, only 
about 1 in 5 eligible patients were audited in 2013. (Section 2, p 24) 
 
     
 
Submission of follow-up data has improved but remains incomplete. (Section 2, p 19) 
 
Only 33% of adult patients audited had complete follow-up data at 3 months.  
 
The proportion is even lower for 12-month follow-up, with only 12% of patients 
recorded as having been followed up at this timepoint. 
 
 
More patient-reported outcome measures 
(PROMs) were completed at the start of 
treatment (30%) than for the previous report 
(14%), although fewer PROMs were completed 
at the 3- and 12-month review points (25% and 
22%, respectively).6 (Section 2, p 28) 
 
 
 
 
 
 
 
96% 
2015 
54% 
2012 
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Recommendations 
1 Sites that prescribe and administer biological therapies to their patients with inflammatory 
bowel disease (IBD) should continue to participate in the national biological therapy audit. They 
should aim to submit complete data on all new starters. This includes data at baseline and at 
least 3- and 12-month follow-up. Sites that enter data to the Personalised Anti-TNF Therapy 
study (PANTs) are counted as participating; these sites are reminded that data on patients not 
applicable for inclusion in the research study should be entered into the biological therapy audit 
web tool so that all new starters on biological therapies are captured. 
 
2 Disease activity should be routinely assessed and monitored, especially at baseline and again at 
3- and 12-month follow-up. 
 
3 Sites should continue to encourage patients to complete patient-reported outcome measures 
(PROMs) at baseline, as they provide an indication of patient outcomes and the quality of care 
delivered to patients. It is important to ensure that PROMs are completed at follow-up.  
 
4 The audit has been extended to include patients started on biosimilar versions of infliximab and 
other biological treatments. Patients newly started on these treatments should now be audited. 
 
5 Sites should use the ‘Export data’ function of the web tool to check the completeness of the 
data entered. Exported data can also be used for any local analyses, which can support quality 
improvement activities. 
 
6 Sites should continue to monitor safety and efficacy over the long term and should stop 
biological therapies in patients who have failed to respond to treatment. 
 
7 The findings and recommendations of this report should be shared at relevant multidisciplinary 
team, clinical governance and audit meetings, and a local action plan for implementing change 
should be devised. 
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Implementing change: action plan  
This action plan has been produced to enable you to take forward the recommendations of this national audit. It can be adapted through the addition of further 
actions that you feel are appropriate for your own service. You can download a copy of this action plan from www.rcplondon.ac.uk/ibd. 
 
National recommendation Action required Staff responsible Progress at your site 
(Include date of review, name 
of individual responsible for 
action) 
1 Sites that prescribe and administer 
biological therapies to their patients 
with inflammatory bowel disease (IBD) 
should continue to participate in the 
national biological therapy audit. They 
should aim to submit complete data on 
all new starters. This includes data at 
baseline and at least 3- and 12-month 
follow-up. Sites that enter data to the 
Personalised Anti-TNF Therapy in 
Crohn’s disease study (PANTs) are 
counted as participating; these sites are 
reminded that data on patients not 
applicable for inclusion in the research 
study should be entered into the 
biological therapy audit web tool so that 
all new starters on biological therapies 
are captured. 
Eligible sites should ensure that all newly started 
patients are entered into the biological therapies audit. 
Have a system in place to ensure that data are collected 
at 3- and 12-month follow-up. 
Consultant 
gastroenterologists 
IBD nurses 
Infusion clinic staff 
 
2 Disease activity should be routinely 
assessed and monitored, especially at 
baseline and again at 3- and 12-month 
follow-up. 
 
Ensure that the relevant disease activity index is 
available in clinical areas.  
Ensure that IBD clinical teams are made aware of its 
availability and importance.  
Disease activity scoring forms for patients can be 
downloaded directly from the biological therapy audit 
web tool (www.ibdbiologicsaudit.org). 
Consultant 
gastroenterologists 
IBD nurses 
Infusion clinic staff 
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National recommendation Action required Staff responsible Progress at your site 
(Include date of review, name 
of individual responsible for 
action) 
3 Sites should continue to encourage 
patients to complete patient-reported 
outcome measures (PROMs) at baseline, 
as they provide an indication of patient 
outcomes and the quality of care 
delivered to patients. It is important to 
ensure that PROMs are completed at 
follow-up.  
Ensure that the PROM forms are available in clinical 
areas.  
Ensure that IBD clinical teams are made aware of their 
availability and importance.  
PROM forms for patients can be downloaded directly 
from the biological therapy audit web tool 
(www.ibdbiologicsaudit.org). 
Consultant 
gastroenterologists 
IBD nurses 
Infusion clinic staff 
 
4 The audit has been extended to include 
patients started on biosimilar versions 
of infliximab and other biological 
treatments. Patients newly started on 
these treatments should now be 
audited. 
Ensure that data on all patients newly started on 
biosimilar versions of drugs are entered into the 
biological therapies audit.  
Have a system in place to ensure that data are collected 
at 3- and 12-month follow-up. 
Consultant 
gastroenterologists 
IBD nurses 
Infusion clinic staff 
 
5 Sites should use the ‘Export data’ 
function of the web tool to check the 
completeness of the data entered. 
Exported data can also be used for any 
local analyses, which can support quality 
improvement activities. 
Ensure that staff are aware that the export function can 
be used at any time.  
Site-level data can be analysed at any time, independent 
of the annual report.  
Data can be exported directly from the biological 
therapy audit web tool by clicking the ‘Export data’ 
function (www.ibdbiologicsaudit.org). 
NHS managers 
Consultant 
gastroenterologists 
 
 
6 Sites should continue to monitor safety 
and efficacy over the long term and 
should stop biological therapies in 
patients who have failed to respond to 
treatment. 
 
In keeping with guidance from the National Institute for 
Health and Care Excellence (NICE), processes should be 
put in place to ensure that patients are assessed at 12 
months. 
Consultant 
gastroenterologists 
Infusion clinic staff 
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National recommendation Action required Staff responsible Progress at your site 
(Include date of review, name 
of individual responsible for 
action) 
7 The findings and recommendations of 
this report should be shared at relevant 
multidisciplinary team, clinical 
governance and audit meetings, and a 
local action plan for implementing 
change should be devised. 
Identify an appropriate time to discuss the results of the 
audit and decide key priority areas for improvement. 
Present the findings and recommendations at an 
appropriate meeting and ensure that action plans for 
implementing change are devised.  
NHS managers 
Consultant 
gastroenterologists 
IBD nurses 
Members of the IBD 
team 
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1: Introduction and methods  
 
Introduction 
Biological therapies are the newest group of drugs to be used in inflammatory bowel disease (IBD). Most 
of these drugs work by targeting a protein in the body called tumour necrosis factor alpha (TNFα). 
Overproduction of this protein is thought to be partly responsible for the chronic inflammation in 
patients with IBD. Biological therapies have revolutionised the treatment of IBD, with usage increasing 
rapidly in the UK over the past few years. Available data suggest that they are effective treatments, with 
a relatively low frequency of adverse events. They remain a significant cost burden for hospitals in the 
UK – approximately £10,000 per patient per year – and thus audit of their effectiveness, safety and 
appropriateness remains a clinical priority. Further information about biological therapies and their 
licensing can be found in section 4, p 30. 
 
Aims of the biological therapies audit 
To assess nationally: 
1 the appropriate use/prescribing of biological therapies in the treatment of IBD 
2 the efficacy of biological therapies in the treatment of IBD 
3 the safety of biological therapies in the treatment of IBD 
4 the views of patients with IBD on their quality of life at defined intervals throughout their use of 
biological therapies.  
 
Methods 
This is a prospective audit, with data collection taking place in ‘real time’ during the clinical appointment 
with the patient. Participating sites are asked to identify and enter data on patients newly started on 
biological therapies. Data entry takes place in the form of ‘submissions’ to a web-based data collection 
tool (www.ibdbiologicsaudit.org). A submission refers to data entered in any of the following 
categories: patient demographics, IBD disease details, initial anti-TNFα treatment, follow-up anti-TNFα 
treatment and IBD-related surgery. Further detail about each of the categories can be found on p 31 of 
this report. 
 
Definition of a ‘site’ 
Lead clinicians are asked to collect and submit data on the basis of a unified IBD service that would be 
registered as a named ‘site’. This is typically a single hospital within a trust / health board, but where 
more than one hospital under a trust / health board offers independent IBD services, data are entered 
for separate ‘sites’. Some organisations that run a coordinated IBD service across several hospitals with 
the same staff participate in the audit as one trust / health board-wide site. 
 
Eligibility and participation 
Sites are eligible to participate in the biological therapies audit if they prescribe and administer 
biological therapy to their patients with IBD. Of the 159 adult trusts / health boards eligible to 
participate in the IBD audit in the UK, 152 are participating in the biological therapies element and/or in 
the Personalised Anti-TNF Therapy in Crohn’s disease (CD) study (PANTs); see below for further 
information). These 152 trusts / health boards provided the 194 sites that submitted data. Further 
information on participation and a list of participating and non-participating sites can be found in 
section 6, p 64 of this report. 
 
PANTs 
This is a 3-year, prospective, uncontrolled, cohort study investigating primary non-response, loss of 
response and adverse drug reactions to infliximab and adalimumab in patients with severe, active, 
luminal CD. The collected clinical data are aligned with data collected by the biological therapy audit. 
Relevant anonymised data from PANTs have been included and analysed in this report. Sites 
participating in PANTs are reminded that patients not eligible for inclusion in this research study should 
15 
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still be entered on to the biological therapy audit web tool so that all new starters are captured. Sites 
submitting data to PANTs are indicated by an asterisk in the list of participating and non-participating 
sites in section 6, p 64 of this report. 
 
Inclusion and exclusion criteria 
Only patients with diagnosed IBD – that is, CD, ulcerative colitis (UC) and IBD type unclassified (IBDU) – 
who have been started on biological therapy for the treatment of their IBD are included. Patients of all 
ages are included in the audit. Sites that do not provide any biological treatment to their patients with 
IBD are excluded from participation. The process of including and excluding data in national analyses is 
detailed in the consort diagram on p 18 of this report. 
 
Denominators 
Denominators throughout the report vary depending on the number of submissions to which the 
analysed data relate. A submission refers to data entered in any of the following categories: patient 
demographics, IBD disease details, initial treatment, follow-up treatment and IBD-related surgery. For 
example, a single patient can have multiple initial or follow-up treatments and may have been treated 
with one or both drug types. The denominators can vary considerably, so readers should review all table 
notes and explanatory text provided within the report. 
 
Data-collection tool 
Security and confidentiality are maintained during data collection by using unique usernames and 
passwords; only the lead clinician at each site can authorise local access. Data can be saved during and 
at the end of an input session, and online help – including definitions and clarifications of data items, 
internal logical data checks and instant feedback mechanisms – ensure that high-quality data are 
collected. For an explanation of the different submission types in the biological therapies audit, please 
see p 31 of this report. 
 
Site-level data 
The small numbers of patients with UC and IBDU mean that site-level data are restricted to patients with 
CD. The IBD programme steering group, having taken statistical advice, has identified a sample size of 
fewer than six patients as potentially compromising patient anonymity in the age and gender fields in 
Table 2. Results in site reports that meet this criterion have therefore been replaced with ‘n<6’. In the 
case of the national report, no data will appear in the ‘Your site’ columns, but these have been left in 
situ to show the format of the individualised site reports. 
 
Evidence 
Guidance referred to within this document is taken from the following sources: 
• IBD Standards Group, 2013. Standards for the healthcare of people who have inflammatory 
bowel disease, IBD standards, 2013 update. www.ibdstandards.org.uk [Accessed 16 July 2015]. 
• Mowat C, Cole A, Windsor A et al, on behalf of the IBD Section of the British Society of 
Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 
2011;60:571–607.  
• National Institute for Health and Care Excellence, 2008. Technology appraisal 163: Infliximab for 
acute exacerbations of ulcerative colitis. www.nice.org.uk/guidance/TA163. [Accessed 16 July 
2015]. 
• National Institute for Health and Care Excellence, 2011. Technology appraisal 187: Infliximab 
(review) and adalimumab for the treatment of Crohn’s disease. 
www.nice.org.uk/guidance/TA187 [Accessed 16 July 2015]. 
• National Institute for Health and Care Excellence, 2015. Technology appraisal 329: Infliximab, 
adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the 
failure of conventional therapy (including a review of TA140 and TA262). 
www.nice.org.uk/guidance/TA329 [Accessed 16 July 2015]. 
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• National Institute for Health and Care Excellence, 2015. Quality standard 81: Inflammatory 
bowel disease. www.nice.org.uk/guidance/QS81 [Accessed 16 July 2015]. 
• Royal College of Physicians, 2014. Experience of inpatients with ulcerative colitis throughout the 
UK. 
• Royal College of Physicians, 2014. National audit of inflammatory bowel disease (IBD) service 
provision. Adult report. 
• Royal College of Physicians, 2014. National clinical audit of inpatient care for adults with 
ulcerative colitis. 
 
Availability of audit results in the public domain 
Full and executive summary copies of this report are available in the public domain via the Royal College 
of Physicians (RCP) website (www.rcplondon.ac.uk/biologics). The national report of results will be 
made available to NHS England; the Department of Health, Social Services and Public Safety in Northern 
Ireland; Healthcare Improvement Scotland; and the Department for Health and Social Services in Wales. 
A number of key indicators for each of the 194 participating sites are published in the public domain in 
section 6, pp 64–85 of this report; these findings are also available via www.data.gov.uk, in line with 
the government’s transparency agenda. 
 
Presentation of results 
National results are presented as percentages for categorical data and as medians and interquartile 
ranges (IQRs) for numerical data. This report summarises data on adults provided by sites that 
registered to participate in the audit and indicated that they provide their IBD service to mainly adult 
patients. A separate report for paediatric IBD services can be viewed on the RCP website 
(www.rcplondon.ac.uk/biologics). When measures are comparable, both adult and paediatric data are 
provided for review. 
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2: Summary of key results 
 
Consort diagram – initial treatment 
On 28 February 2015, 9460 individual adult patient demographic submissions had been entered on the 
web tool. Readers are reminded that individual results are often a subset of this number and that the 
context and actual number of cases should be considered when interpreting findings. Fig 1 is therefore 
integral to understanding the patient numbers and the reasons that patients were excluded from 
analysis when considering the results in this report. 
 
Fig 1 Consort diagram for initial treatment. CD = Crohn’s disease; IBDU = inflammatory bowel disease 
type unclassified; UC = ulcerative colitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All analyses within this report include all patients who were newly started on biological therapies since 
12 September 2011 (the start of the audit). A consort diagram detailing patient numbers and reasons for 
exclusion from follow-up treatment data can be found in Appendix 3, p 96. 
n=2001 
Adalimumab Patients: 
CD (n=1894) 
UC (n=83) 
IBDU (n=24) 
n=2717 
Infliximab patients: 
CD (n=2006) 
UC (n=633) 
IBDU (n=78) 
 n=7395  
Patients with  
first initial treatments 
n=820  
Patients from Personalised 
Anti-TNF Therapy in CD 
study (PANTs)  
n=3111,  
Patients excluded because 
initial treatment was before 
12 September 2011 or 
patient was not a new 
starter on biological 
therapies n=3898  
Patients with complete audit 
data (demographic, disease, 
and initial treatment data) 
n=7009  
Patients with  
demographic, disease  
and initial treatment data 
n=8108  
Initial treatments 
n=7381  
Patients with  
disease details 
n=9460  
Patients with  
demographic details 
n=4718  
Patients in  
initial treatment analysis 
18 
© Healthcare Quality Improvement Partnership 2015 
National clinical audit of biological therapies. Adult report. September 2015. UK IBD audit 
Key data tables 
 
Understanding these results 
The tables in this section use key data items to address the objectives of the biological therapies audit 
and provide an overall view of the main characteristics of the included patients. It is important to note 
that this report is patient focused rather than treatment based; therefore, although some of the tables 
may appear similar to those in the reports produced in 2013 and 2014, these analyses have been 
conducted differently, so it is not advisable to compare directly with those in the previous reports. 
 
Table 1 Patient summary 
This table provides a summary of the patients and treatments included in the national analysis. The 
consort diagram in Fig 1 (p 18) shows that only those patients with at least one initial treatment were 
included in the analyses. Thereafter, the numbers reduce based on whether patients were recorded as 
having been followed up at 3 and 12 months after initial treatment. For the follow-up timepoint, a 1-
month window either side was used in order to best capture patients – eg for 3-month follow-up, data 
entered 60–120 days after initial treatment were included. 
  
Patient group Initial treatment 
(n) 
3-month follow-up 
(n) 
12-month follow-
up (n) 
CD patients 3900 1343 520 
Adalimumab 1894 525 181 
Infliximab 2006 818 339 
UC patients 716 176 52 
Adalimumab 83 19 3 
Infliximab 633 157 49 
IBDU Patients 102 42 14 
Adalimumab 24 12 2 
Infliximab 78 30 12 
Total patients 4718 1561 586 
YOUR SITE - Patients with CD     
CD = Crohn’s disease; IBDU, inflammatory bowel disease type unclassified; UC, ulcerative colitis. 
 
Table 2 Key items to compare data from adult and paediatric patients with CD 
This table compares demographic data for adult and paediatric patients with CD treated with infliximab 
or adalimumab. The denominators differ when questions were not answered. 
 
General patient characteristics 
CD 
YOUR SITE 
Adult Paediatric 
Total number of patients n=3900 n=579  
Gender: male (%, n/N) 47% (1837/3884) 63% (365/579)  
Age at diagnosis, years, median (IQR) 
 
n=3739 
27 (20, 39) 
n=566 
13 (10, 14)  
Age at initial treatment, years, median (IQR) 
 
n=3894 
36 (26, 49) 
n=578 
14 (12, 16)  
Time from diagnosis to treatment, years, 
median (IQR) 
n=3739 
4 (1, 12) 
n=567 
1 (1, 2)  
CD = Crohn’s disease; IQR = interquartile range. 
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Table 3 Disease distribution 
Crohn’s disease can be classified in terms of severity – mild, moderate or severe – or by the Montreal 
classification, which proposes the maximum extent of involvement as the acute factor.7 This table 
describes the distribution of CD across audited adult and paediatric patients treated with adalimumab 
or infliximab. 
 
Disease distribution 
CD 
YOUR SITE Adult  
(%, n/N) 
Paediatric  
(%, n/N) 
 n=3900 n=579  
 
Terminal ileum (L1) 27% (1035/3849) 12% (68/573)  
 
Colonic (L2) 31% (1188/3849) 31% (176/573)  
 
Ileocolonic (L3) 36% (1380/3849) 49% (283/573)  
 
None of these 6% (239/3849) 8% (46/573)  
 
Any part of the gut 
proximal to the terminal 
ileum (L4) 
Yes= 
45% (1312/2925) 
Yes= 
71% (352/495)  
 
Perianal involvement Yes= 31% (838/2688) 
Yes=  
47% (187/397)  
CD = Crohn’s disease. 
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Table 4 Response to therapy 
This table shows response to therapy in patients with CD who were treated with infliximab or 
adalimumab. Results are displayed at the 3-month follow-up timepoint. The Harvey–Bradshaw index 
(HBI) is used to quantify disease activity for adult patients with CD. The Paediatric Crohn’s Disease 
Activity Index (PCDAI) is used to measure disease activity for paediatric patients with CD. The 
denominators change when dates of diagnosis for patients are missing. 
 
CD patient group Response to treatment* at 3-month follow-up (%, n/N) 
Time from diagnosis to 
initial treatment in years <1 1–2 3–5 6–10 >10 Total 
Adult 79% (121/154) 
79% 
(115/145) 
80% 
(89/112) 
81% 
(86/106) 
77% 
(159/207) 
80% 
(570/715) 
Paediatric 73% (35/48) 
78% 
(52/67) 
82% 
(18/22) 
75%  
(9/12) 
0%  
(0/0) 
77% 
(114/149) 
YOUR SITE       
*Decrease of >3 in Harvey–Bradshaw index for adult patients and >15 in Paediatric Crohn’s Disease Activity Index for paediatric 
patients. 
CD = Crohn’s disease.  
 
Table 5 Remission achieved 
This table shows whether remission was achieved in patients with CD who were treated with infliximab 
or adalimumab. Results are displayed at the 3-month follow-up timepoint. As before, the HBI was used 
to quantify disease activity in adults with CD and the PCDAI to measure disease activity for paediatric 
patients with CD, and the denominators change when dates of diagnosis for patients are missing. 
 
CD patient group Remission* achieved when followed up at 3 months (%, n/N) 
Time from diagnosis to 
initial treatment in years <1 1–2 3–5 6–10 >10 Total 
Adult  68% (105/155) 
67% 
(101/150) 
72% 
(83/116) 
71% 
(78/110) 
64% 
(135/210) 
68% 
(502/741) 
Paediatric  59% (30/51) 
66% 
(45/68) 
68% 
(15/22) 
75%  
(9/12) 
0%  
(0/0) 
55%  
(54/99) 
YOUR SITE       
*Harvey–Bradshaw index (HBI) score <4 for adult patients and Paediatric Crohn’s Disease Activity Index (PCDAI) score <10 for 
paediatric patients. 
CD = Crohn’s disease.  
 
Table 6 Concomitant therapy 
This table shows the percentage of all adult patients with CD on any immunosuppressant or steroid as 
concomitant therapy during their treatment with biological therapies. Data collected in PANTs have not 
been included in this analysis owing to time constraints but are expected to be included in the next 
report. 
 
Type of concomitant therapy  
Treatment time (%, n/N) 
Initial treatment 3-month follow-up 12-month follow-up 
Immunosuppressants*  53% (1644/3080) 48% (479/1000) 48% (192/404) 
YOUR SITE    
Steroids†  27% (819/3080) 6% (64/1000) 5% (21/404) 
YOUR SITE    
*Immunosuppressants include azathioprine, mercaptopurine and methotrexate.  
†Steroids include budesonide, hydrocortisone, methylprednisolone and prednisolone. 
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Table 7 Analysis of results over time 
This table compares some key results over time for adults with IBD included in the audit according to 
reporting timescales. A reduction in site participation between 2014 and 2015 was due to the 
reconfiguration of services across sites during the year. 
 
Result 
Audit period 
June 2012 
(12.09.11–
29.02.12) 
August 2013 
(01.03.12–
28.02.13) 
September 2014 
(01.03.13–
28.02.14) 
September 2015 
(01.03.14–
28.02.15) 
Participation in the biological therapy audit 
Adult sites with data 
included in analysis (n) 78 94 143 134 
Adult patients audited initiating biological therapies 
Patients with CD (n) 347 837 1252 1464 
Patients with UC (n) 49 146 236 285 
Patients with IBDU (n) 20 29 22 31 
Total (n) 416 1012 1510 1780 
Treatment time 
Time from diagnosis to 
initial treatment  
(years, median IQR) 
n=413 
4 (1, 11) 
n=1007 
4 (1, 11) 
n=1475 
4 (1, 12) 
n=1657 
4 (1, 10) 
Adverse events 
Adverse events reported at 
initial treatment (%, n/N) 2% (9/416) 3% (26/1012) 3% (40/1510) 2% (42/1780) 
Disease activity reported at initial treatment for adult patients 
HBI score, median (IQR) n=226 6 (0, 10) 
n=421 
9 (6, 12) 
n=710 
8 (4, 11) 
n=925 
7 (4, 10)* 
SCCAI score, median (IQR) n=44 6 (0, 9) 
n=90 
9 (6, 11) 
n=99 
8 (6, 11) 
n=129 
9 (6, 12) 
Adult patients with CD on concomitant therapies at initial treatment 
Immunosuppressants  
(%, n/N) 54% (189/347) 58% (482/837) 38% (473/1252) 34% (500/1464)* 
Steroids  
(%, n/N) 27% (93/347) 27% (222/837) 22% (274/1252) 16% (230/1464) 
*p<0.001. 
CD = Crohn’s disease; HBI = Harvey–Bradshaw index; IBDU = inflammatory bowel disease type unclassified; IQR = interquartile 
range; SCCAI = Simple Clinical Colitis Activity Index; UC = ulcerative colitis. 
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Table 8 National comparison of key results for adults with CD 
This table depicts national variation in the results of the biological therapy audit between England, 
Northern Ireland, Scotland and Wales. It only includes sites that submitted enough data to be included 
in the national analysis. A full list of participating and non-participating sites can be found in section 6, 
p 64 of this report. 
 
Result 
Country 
England Northern Ireland Scotland Wales 
Sites participating in the audit (%, n/n) 84%  (141/167) 
75%  
(9/12) 
52%  
(11/21) 
44%  
(7/16) 
Patients audited (n) 3531 90 126 153 
Time from diagnosis to initial treatment 
(years, median (IQR)) 
n=3379 
4 (1, 12) 
n=90 
4 (1, 10) 
n=119 
5 (1, 12) 
n=151 
4 (1, 12) 
Patients with an adverse reaction 
recorded during initial treatment (%, n/n) 
3%  
(97/3531) 
2%  
(2/90) 
2%  
(3/126) 
3%  
(4/153) 
Disease severity (HBI) at initial treatment, 
median (IQR) 
n=2082 
8 (4, 11) 
n=27 
9 (5, 11) 
n=66 
6 (3, 9) 
n=109 
7 (4, 10) 
Patients with follow-up recorded at 
3 months (%, n/N) 
35% 
(1238/3531) 
11%  
(10/90) 
31%  
(39/126) 
37%  
(56/153) 
Patients on biological therapy who were 
appropriately prescribed anti-TNFα in 
compliance with NICE technology 
appraisal 1872 criterion 1.1 (%, n/N) 
46%  
(949/2082) 
56%  
(15/27) 
33%  
(22/66) 
46%  
(50/109) 
HBI = Harvey–Bradshaw index; IQR = interquartile range; TNFα = tumour necrosis factor alpha. 
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Tables 9 and 10 Biological therapies audit case ascertainment 
These two tables compare results as reported in the National audit of inflammatory bowel disease 
(IBD) service provision (September 2014).8 Sites participating in this audit were asked to report on the 
number of patients with IBD who had newly started on infliximab or adalimumab between 1 January 
2013 and 31 December 2013. Sites were able to indicate whether the figure was an estimate or was 
taken from an existing database of patients. The number of patients reported as newly started on 
biological therapy in the organisational audit was then compared with the actual number of patients 
audited in the biological therapy audit for the same time period and used to produce a case 
ascertainment figure.  
 
Patients newly started on adalimumab National YOUR SITE 
Patients with IBD who were newly started on adalimumab 
between 1 January 2013 and 31 December 2013, as reported 
in organisational audit (September 2014)8 (n) 
2692  
(reported by 171 sites)  
Newly started patients – estimated (n) 949  (reported by 69 sites)  
Newly started patients – taken from a database (n) 1728  (reported by 101 sites)  
Newly started patients – taken from unknown source (n) 15  (reported by 1 site)  
Patients with IBD entered into biological therapies audit who 
were newly started on adalimumab between 1 January 2013 
and 31 December 2013 (n) 
566  
Case ascertainment rate (%) 21%  
IBD = inflammatory bowel disease. 
 
Patients newly started on infliximab National YOUR SITE 
Patients with IBD who were newly started on infliximab 
between 1 January 2013 and 31 December 2013, as reported 
in organisational audit (September 2014)8 (n) 
3400 
(reported by 170 sites)  
Newly started patients – estimated (n) 1330 (reported by 68 sites)  
Newly started patients – taken from a database (n) 2048 (reported by 101 sites)  
Newly started patients – taken from unknown source (n) 22 (reported by 1 site)  
Number of patients with IBD who were newly started on 
infliximab between 1 January 2013 and 31 December 2013,  
as entered into biological therapies audit (n) 
793   
Case ascertainment rate (%) 23%  
IBD = inflammatory bowel disease. 
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Audit objectives 
Safety  
 
Table 11 Adverse events 
This table shows the percentage of all adult patients for whom an adverse reaction was recorded during 
their treatment, by type of reaction. 
 
Adverse event (%, n) Initial treatment (n=4718) 
3-month follow-up 
(n=1516) 
12-month follow-up 
(n=586) 
Adverse event recorded 
Yes= 3% (117) 8% (126) 6% (33) 
Abdominal pain 0.04% (2) 0.3% (5) 0.2% (1) 
Alopecia 0% (0) 0.1% (1) 0.2% (1) 
Angioedema of upper airway 0.06% (3) 0.1% (2) 0.2% (1) 
Arthralgia 0.3% (13) 0.6% (10) 0% (0) 
Blood abnormality 0.02% (1) 0.4% (7) 0% (0) 
Bronchospasm 
(cough/wheeze/dyspnoea) 0.3% (13) 0.5% (8) 0.5% (3) 
Cardiac failure 0% (0) 0% (0) 0% (0) 
Chest pain 0.1% (5) 0.1% (1) 0% (0) 
Chills 0.04% (2) 0.1% (1) 0.9% (5) 
Confirmed demyelination 0.04% (2) 0% (0) 0% (0) 
Death 0% (0) 0.1% (1) 0% (0) 
Difficulty breathing 0% (0) 0.2% (3) 0% (0) 
Dizziness 0.3% (12) 0.4% (6) 0% (0) 
Fatigue 0.1% (5) 0.3% (5) 0.2% (1) 
Fever 0.2% (9) 0.2% (3) 0% (0) 
Flushing 0.3% (16) 0.7% (11) 0.2% (1) 
Headache 0.4% (21) 0.4% (6) 0.5% (3) 
Hypotension 0.1% (5) 0.3% (4) 0% (0) 
Infection 0.1% (4) 2% (36) 2% (11) 
Injection site reaction 0.1% (4) 0.2% (3) 0% (0) 
Itching 0.3% (12) 0.3% (5) 0.2% (1) 
Limb weakness 0.04% (2) 0.1% (1) 0% (0) 
Malignancy 0% (0) 0% (0) 0% (0) 
Nausea 0.4% (17) 0.7% (11) 0.2% (1) 
Panic attacks 0.1% (5) 0.1% (1) 0% (0) 
Rash 0.4% (18) 1% (21) 0.3% (2) 
Serum sickness-like reaction 0% (0) 0% (0) 0% (0) 
Urticaria 0.04% (2) 0.3% (4) 0% (0) 
Other 0.7% (32) 2% (24) 2% (10) 
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Efficacy 
 
Disease activity for adult patients at the time of initial treatment was compared with that at the follow-
up nearest to 3 and 12 months from the date of the initial treatment. Follow-up data include only those 
patients who had an initial treatment. 
 
Table 12 Disease activity – CD 
When severity of CD is classified by HBI, a score <5 is considered to be clinical remission and >16 is 
considered to be severe disease.  
 
HBI score Initial treatment 3-month follow-up 12-month follow-up 
Adalimumab, median (IQR) n=1081 8 (4, 11) 
n=264 
3 (1, 6) 
n=95 
3 (1, 5) 
Infliximab, median (IQR) n=1201 7 (4, 10) 
n=524 
2 (1, 5) 
n=215 
2 (0, 4) 
Total n=2282 8 (4, 10) 
n=788 
3 (1, 6) 
n=310 
2 (0, 5) 
YOUR SITE     
HBI = Harvey–Bradshaw index; IQR = interquartile range. 
  
Table 13 Disease activity – UC 
When severity of UC is classified by SCCAI, a score of <3 is considered to be remission and >13 is 
considered to be severe disease. 
 
SCCAI score  Initial treatment 3-month follow-up 12-month follow-up 
Adalimumab, median (IQR) n=41 7 (6, 8) 
n=9 
3 (1, 6) n=2 
Infliximab, median (IQR) n=321 9 (6, 11) 
n=77 
2 (0, 6) 
n=18 
3 (1, 4) 
Total n=362 9 (6, 11) 
n=86 
2 (0, 5) 
n=20 
3 (1, 4) 
IQR = interquartile range; SCCAI = Simple Clinical Colitis Activity Index. 
  
Table 14 Surgery 
This table shows combined surgical activity for patients with CD, UC and IBDU recorded in the 6 months 
before and after treatment with biological therapies. Further information about the surgical data 
collected in the biological therapies audit can be found on p 60 of this report. 
 
Surgical activity Adult  (%, n/N)) 
Paediatric  
(%, n/N) 
Pre-treatment surgery recorded   
 Yes 23% (1066/4718) 9% (65/696) 
Patients with surgery recorded 6 months before 
starting biological therapies 5% (244/4718) 6% (39/696) 
Patients with surgery recorded 6 months after 
starting biological therapies  3% (157/4718) 5% (31/696) 
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Appropriateness of prescribing anti-TNFα  
 
Detailed information about the NICE guidance and recommendations for use of biological therapies in 
patients with IBD in the UK can be found in section 4, p 30 of this report. In Tables 15 and 16, NICE 
criterion 1.1 from technology appraisal 1872 and criterion 1.1 from technology appraisal 3293 have been 
used to assess the appropriateness of prescribing biological therapy.  
 
Table 15 Compliance with NICE technology appraisal 187 
This table shows compliance with criterion 1.1 of NICE technology appraisal 1872 in adult patients with 
CD. Patients with no recorded HBI were excluded from this analysis. 
 
NICE technology appraisal 187 National CD data, % (n/N) YOUR SITE 
Criterion 1.1 Infliximab and adalimumab are recommended as treatment options for adults with severe 
active CD if (a) the disease has not responded to conventional therapy or (b) the person is intolerant of 
or have contraindications to conventional therapy (mercaptopurine, azathioprine, methotrexate, 
prednisolone, budesonide, methylprednisolone or hydrocortisone) 
Patients with CD on biological therapy with HBI score ≥8 
before starting anti-TNFα treatment  51% (1159/2282)  
Patients with CD who were treated with conventional 
therapy at time of or prior to starting biological therapy  86% (1951/2282)  
Patients with CD on biological therapy who were 
appropriately prescribed anti-TNFα treatment in compliance 
with criterion 1.1 of NICE technology appraisal 187  
45% (1035/2282)  
CD = Crohn’s disease; HBI = Harvey–Bradshaw index; NICE = National Institute for Health and Clinical Excellence; TNFα = tumour 
necrosis factor alpha. 
   
Although compliance with NICE guidance seems to be low for patients with CD, many patients are likely 
to have had the prerequisite disease activity before starting biological therapy. Many patients will have 
been treated with corticosteroids, resulting in the observed values. 
 
Table 16 Compliance with NICE technology appraisal 329 
This table shows compliance with criterion 1.1 of NICE technology appraisal 3293 in adult patients with 
UC. Patients with no recorded SCCAI were excluded from this analysis. 
 
NICE technology appraisal 329 National UC data (%, n/N) 
Criterion 1.1 Infliximab, Adalimumab and golimumab are recommended as treatment options for 
adults with moderate to severe active UC (a) whose disease has responded inadequately to 
conventional therapy or (b) are intolerant of or have contraindications to conventional therapy 
(mercaptopurine, azathioprine, methotrexate, prednisolone, budesonide, methylprednisolone or hydrocortisone) 
Patients on biological therapy with SCCAI score ≥5 before starting anti-TNFα 
treatment  
87%  
(276/318) 
Patients who were treated with conventional therapy at time of or prior to 
starting biological therapy 
95%  
(301/318) 
Patients on biological therapy who were appropriately prescribed anti-TNFα 
therapy in compliance with criterion 1.1 of NICE technology appraisal 329  
82%  
(262/318) 
SCCAI = Simple Clinical Colitis Activity Index; NICE = National Institute for Health and Care Excellence; TNFα = tumour necrosis 
factor alpha; UC = ulcerative colitis. 
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Patient-reported outcome measures 
 
Table 17 PROMs questionnaire for IBD (IBD-PROM) 
This table gives completion rates and results of the IBD-PROM questionnaires used in the biological 
therapies audit – the EQ-5D9 and Crohn’s and ulcerative colitis questionnaire (CUCQ)-1210 – for all adult 
patients calculated. Total EQ-5D scores range from 0 (worst health / death) to 1 (best health), with an 
increase in score denoting improved health. Total CUCQ-12 scores range from 0 (best health) to 168 
(poor health), with each question scored between 0 (best) and 14 (poor). Further information about the 
EQ-5D and CUCQ-12 can be found on pp 62–63 of this report. 
 
IBD-PROM Initial treatment 3-month follow-up 
12-month follow-
up 
Patients with completed IBD-PROM 
(%, n/N) 
30%  
(1416/4718) 
25%  
(384/1561) 
22%  
(129/586) 
YOUR SITE number of patients with 
IBD-PROM completed    
Patients with EQ-5D data completed, 
(%, n/N) 
97%  
(1367/1416) 
94%  
(361/384) 
44%  
(57/129) 
EQ-5D score, median (IQR) 0.76 (0.66, 0.85) 0.80 (0.73, 1) 0.80 (0.69, 1) 
Patients with CUCQ-12 data 
completed (%, n/N) 
89%  
(1256/1416) 
87%  
(332/384) 
87%  
(112/129) 
CUCQ-12 score, median (IQR) 68 (39, 100) 34 (14, 60) 27 (10, 49) 
CUCQ = Crohn's and ulcerative colitis questionnaire; IBD = inflammatory bowel disease; IQR = interquartile range; PROMs = 
patient-reported outcome measures. 
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3: Background information 
 
The burden of inflammatory bowel disease 
The inflammatory bowel diseases UC and CD are lifelong inflammatory conditions that involve the 
gastrointestinal tract. The incidence of IBD has risen dramatically in recent decades and continues to do 
so; it is reported to be as high as 24.3 and 12.7 per 100,000 persons per year in Europe for UC and CD, 
respectively. The reported prevalence in Europe is as high as 505 and 322 per 100,000 persons for UC 
and CD, respectively.11 Inflammatory bowel disease first presents most commonly in the second and 
third decades of life, but much of the recent increase has been observed in childhood, notably with CD 
in children increasing threefold in 30 years. Between 20% and 30% of patients with UC will require 
colectomy, and about 50–70% of patients with CD require surgery. The main symptoms of both 
conditions include diarrhoea, abdominal pain, anaemia and an overwhelming sense of fatigue, with, for 
some patients, associated features such as arthritis, anal disease, fistulae, abscesses and skin problems, 
which can also contribute to poor quality of life. In addition, IBD has wide-ranging effects on growth and 
pubertal development, psychological health, education and employment, family life, fertility and 
pregnancy. Effective multidisciplinary care can attenuate relapse, prolong remission, treat complications 
and improve quality of life. 
 
The UK IBD audit 
The UK IBD audit seeks to improve the quality and safety of care for all patients with IBD throughout the 
UK by auditing individual patient care and the provision and organisation of IBD service resources and by 
reporting on inpatient experience and PROMs. The biological therapies audit is one element of the 
wider UK IBD audit. 
 
This report follows the national reports published in 2012, 2013 and 2014. It builds on the previous 
reports as a continuous audit with increasing rates of participation, and it provides further evidence 
about the safety, efficacy and appropriate use of biological therapies. Furthermore, it enables 
participating sites to benchmark their performance against national data. All data should be considered 
within the context of the actual number of treatments. 
 
Further information on the work of the UK IBD audit project can be accessed via the IBD page of the RCP 
website (www.rcplondon.ac.uk/ibd).  
 
The benefits of the biological therapies audit 
The biological therapies audit is an electronic register of patients receiving treatment and enables IBD 
teams to: 
• monitor the disease activity of patients over the course of their treatment with biological drugs 
• monitor and encourage improved management at patient and service levels, data on adverse 
events, dose escalation and treatment regimens 
• capture the views of patients locally on their quality of life at intervals throughout their treatment 
• benchmark local results against national-level data 
• generate individual patient summaries 
• generate letters detailing treatment plans 
• assess compliance with the IBD standards and NICE quality standard 81.1,4 
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4: The biological therapies audit 
 
What is the role of biological therapy in the treatment of IBD? 
Infliximab 
Infliximab (Remicade®) is a chimeric anti-TNFα monoclonal antibody with potent anti-inflammatory 
effects that are possibly dependent on apoptosis of inflammatory cells. Controlled trials have 
demonstrated efficacy in both active and fistulating CD. Infliximab is typically administered via an 
intravenous infusion during a hospital appointment under the supervision of a suitably qualified health 
professional. 
 
Adalimumab 
Adalimumab (Humira™) is a recombinant human immunoglobulin (IgG1) monoclonal antibody 
containing only human peptide sequences. Adalimumab is typically delivered via a self-administered 
injection. Patients are provided with a home supply of the medication and, following tuition and close 
monitoring, are able to manage their own treatment with regular medical follow-up. 
 
Approval in the UK 
In multi-technology appraisal 187 for patients with CD,2 NICE made the following recommendations: 
• Infliximab and adalimumab may be used within their licensed indications as treatment options 
for adults with severe active CD, whose disease has not responded to conventional therapy 
(including immunosuppressive and/or corticosteroid treatments).  
• Infliximab has been recommended for the treatment of active fistulating CD in patients whose 
disease has not responded to conventional therapy or have medical contraindications for such 
therapies. 
• Infliximab is recommended for the treatment of people aged 6–17 years with severe, active CD, 
whose disease has not responded to conventional therapy (including corticosteroids, 
immunomodulators and primary nutrition therapy) or have contraindications to conventional 
therapy. 
• Infliximab and adalimumab should be given as a planned course of treatment until treatment 
failure (including the need for surgery) or until 12 months after the start of treatment, 
whichever is shorter. Patients’ disease should then be reassessed to determine whether 
ongoing treatment is still clinically appropriate.  
 
In multi-technology appraisal 329 for patients with UC,3 NICE made the following recommendations: 
• Infliximab and adalimumab may be used within their licensed indications as treatment for 
moderate to severe active UC in adults whose disease has responded inadequately to 
conventional therapy or who cannot tolerate or have medical contraindications for such 
therapies.  
• Infliximab has been recommended for treating severely active UC in children and young people 
aged 6–17 years whose disease has responded inadequately to conventional therapy or who 
cannot tolerate or have medical contraindications for such therapies.  
• Infliximab or adalimumab should be given as a planned course of treatment until treatment 
failure (including the need for surgery) or until 12 months after the start of treatment, 
whichever occurs first. Patients’ disease should then be reassessed to determine whether 
ongoing treatment is still clinically appropriate. 
 
In technology appraisal 163,12 NICE made the following recommendation: 
• Infliximab as an option for the treatment of acute exacerbations of severely active UC only in 
patients for whom ciclosporin is contraindicated or clinically inappropriate.  
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Data entry into the biological therapies audit 
Data entry takes place in the form of ‘submissions’ to a web-based data collection tool. A submission 
refers to data entered in any of the following categories: patient demographics, IBD details, initial 
treatment, follow-up treatment and IBD-related surgery. Once all mandatory fields are completed 
within a category, the data are locked to form a completed submission, and they are then suitable for 
inclusion in national findings. Only locked data can be viewed by the UK IBD audit project team. The full 
audit dataset is available from the RCP website (www.rcplondon.ac.uk/biologics).  
 
Patient demographics category 
Patients are identified prospectively when the decision to treat using biological therapies is made by a 
clinician. The demographic details of this patient are entered using the web tool; this includes a number 
of patient identifiers that are pseudonymised at the point of data entry and are visible only to the 
participating site. Details of the patient’s consultant and GP can also be entered, although this is not 
mandatory for the audit. 
 
Disease details category 
This section requires sites to provide details of the patient’s IBD history, including the extent of their 
disease, any related comorbid conditions and details of any surgical procedures undertaken prior to the 
initiation of biological therapies. 
 
Initial treatment category 
This section collects details of the initial or baseline treatment. The site indicates whether the patient 
has CD, UC or IBDU and whether they are being treated with adalimumab or infliximab. The system then 
generates appropriate questions for these options. Information is collected about pre-treatment 
investigations and screening up to the point of completion or abandonment of the treatment, with 
details of any treatment reactions that occur.  
 
Follow-up treatment category 
Each follow-up treatment that is entered must relate to a previously entered initial treatment 
submission. An unlimited number of follow-up treatments can be completed to allow outgoing data 
collection as the patient continues to be treated with biological therapies. The outcome of each follow-
up treatment – that is, whether treatment will continue or be stopped – must be provided. Details of 
any adverse events are recorded for each follow-up treatment. 
 
IBD-related surgery category 
Details of IBD-related surgery can be added to the web tool at any time. A prompt to update this section 
of the web tool appears at the conclusion of all initial and follow-up treatment submissions. This allows 
identification of any escalation of treatment that is required while a patient is being treated with 
biological therapy. 
 
PROMs category 
Data on PROMs are collected at initial treatment and can then be recorded at any additional follow-up. 
For the purpose of the audit, the PROMs completed at 3- and 12-month follow-up treatments are of 
interest. For further information about PROMs data, see pp 62–63. 
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Continued development of the biological therapies audit web tool 
The biological therapies audit web tool has been continually updated and developed in line with the 
requirements identified through feedback from participants and to reflect emerging evidence. Some 
examples of the adaptations made to date are summarised below.  
 
Biosimilars 
From March 2015, to reflect emerging evidence and changing practice, the biological therapies audit 
was expanded to allow auditing of patients who are newly started on biosimilar versions of the 
biological drugs. 
 
Existing patients 
This was one of the first adaptations of the system and allowed the inclusion of data for patients already 
established on biological therapy in addition to those newly started on these drugs. This allowed sites to 
begin to build their own local registers of patients being treated with biological therapies. This report 
does not contain analyses of data entered for patients already established on biological therapy; data 
for these patients are collected only by those sites that wish to use the data at a local level. 
 
Reporting functions 
Sites can produce patient and treatment summary reports when required; these are summarised briefly 
below. 
Patient summary report  
This is a printable summary of all treatments provided for a specific patient over the course of their 
management; details of any adverse events, acute reactions and relevant surgery are listed. A graphical 
display of the patient’s disease severity scores over time allows a simple visual representation of the 
success/failure of treatment to encourage action when required. The patient summary can be filed in 
the patient’s case notes or provided with an accompanying letter to the patient’s GP. 
Treatment summary report 
This is a printable summary of any isolated initial or follow-up treatment; again, this can be filed in the 
case notes to avoid duplication of effort or included in correspondence with a GP to inform them of the 
treatment provided to their patient on any particular occasion. 
 
Data import function 
The ‘Import data’ function allows users to upload data held in other spreadsheets or registers directly 
into the biological therapy audit web tool through a simple template. This avoids duplication of both 
effort and data entry on sites. 
 
Reduction of mandatory fields 
Following feedback from users regarding the length of time taken to enter submissions onto the web 
tool, the number of mandatory fields is under constant review and is regularly reduced to make the 
process of entering and locking data faster and simpler. 
 
Download function 
Users are able to download their previous site reports, printable versions of the audit tools, help notes 
and a user guide to assist them with data entry.  
 
Data export function 
Users are able to export all data that they have submitted since the start of the audit directly from the audit web 
tool. Data are exported in the form of an editable Excel file. 
 
32 
© Healthcare Quality Improvement Partnership 2015 
National clinical audit of biological therapies. Adult report. September 2015. UK IBD audit 
Dashboard 
The dashboard is the latest development for the web tool. It is split into various sections, each giving sites a glance at their activity on the audit to date. Fig 2 
outlines the functions available on the dashboard. 
 
Fig 2 Functions of the biological therapy audit dashboard 
 
Patient summary 
This gives an overview of how 
many patients have been 
added to the web tool by the 
site. It also flags up any 
patients for whom a follow-up 
treatment has not been 
recorded in the last 90 days. 
 
Performance summary 
This gives the site an idea of 
how well they are performing in 
terms of locking their complete 
submissions. A happy, neutral or 
unhappy face is displayed 
depending on the percentage of 
locked submissions. 
 
Submissions summary 
This pie chart displays locked 
versus unlocked submissions. 
When the link is clicked, the 
site can see all of their 
unlocked submissions. 
 
Patients initiating 
biologics graph 
This shows how many 
patients the site has 
started on each of the 
different biological 
therapies. 
 
Activity over time 
This gives sites an 
overview of submissions 
entered in each category 
over time, including the 
year of data entry. 
33 
© Healthcare Quality Improvement Partnership 2015 
National clinical audit of biological therapies. Adult report. September 2015. UK IBD audit 
System security of the biological therapies audit web tool 
The document Biological therapies audit system and hosted server security details outlines the system 
security information provided to all sites invited to participate in the audit and is available on the RCP 
website (www.rcplondon.ac.uk/biologics).13 The document gives an overview of the security measures 
in place, while providing assurance that security procedures designed by Microsoft and other industry-
standard bodies have been followed. The contracted system developer also implemented the 
recommended procedures contained within the NHS document Securing web infrastructure and 
supporting services good practice guideline.14  
 
Further details can be found on the following: physical data centre (location, security, admission control, 
climatisation, electricity and fire protection), operating system (version, user access, security, 
encryption, updates and patches, and backups), database software (version, user access and encryption) 
and application software (source control, user access and encryption).  
 
The purpose of collecting patient-identifiable data was to make the system useful for staff at a local site 
level by enabling full monitoring and interpretation of the data for the purpose of immediate local 
service improvement and patient care. Patient-identifiable data can be viewed only by registered 
members of the local team, whose access to the site will have been approved via the local clinical lead 
(nearly always a consultant gastroenterologist). Sites using the web tool cannot view data entered at 
other participating sites. The UK IBD audit project team have administrative control to analyse 
anonymised data only and are not able to view any patient-identifiable information.  
 
In accordance with the principles of the Data Protection Act, sites participating in the biological 
therapies audit are reminded that patients should be informed of the use of their data by means of the 
information leaflets and posters provided by the UK IBD audit project team. 
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5: Full national audit results tables 
 
Crohn’s disease details 
 
CD: disease details  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=2006) 
YOUR SITE National 
(n=1894) 
YOUR SITE 
Diagnosis 
Maximal disease distribution at the time of 
decision to initiate biological therapy, as 
defined by the Montreal classification 
(n=1973) (n=1876) 
Terminal ileum (L1) 25% (501)  29% (534)  
Colonic (L2) 34% (671)  28% (517)  
Ileocolonic (L3) 34% (678)  37% (702)  
None of these 6% (123)  7% (123)  
Any part of the gut proximal to the terminal 
ileum (L4) (n=1438)  (n=1487)  
Yes 42% (604)  48% (708)  
Perianal involvement? (n=1357)  (n=1331)  
Yes 36% (484)  27% (354)  
Time between date of diagnosis and date of 
initial treatment (n=1912)  (n=1823) 
<1 year 26% (497)  18% (330)  
1–2 years 18% (351)  20% (367)  
3–5 years 15% (287)  16% (294)  
6–10 years 15% (287)  17% (314)  
>10 years 26% (490)  28% (518)  
CD = Crohn’s disease. 
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Crohn’s disease initial treatment 
 
CD: initial treatment  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=2006) 
YOUR SITE National 
(n=1894) 
YOUR SITE 
Consent 
Was informed consent to receive anti-TNFα treatment taken from this patient? 
Yes 98% (1973)  99% (1872)  
No 2% (33)  1% (22)  
If yes, was this verbal or written?  (n=1973)  (n=1872)  
Verbal 63% (1247)   63% (1175)  
Written 37% (726)  37% (697)  
Treatment details 
Time between date of decision to start and date of initial treatment (first loading dose) 
Median (IQR) time (days) 16 (6, 36)  21 (10, 42)  
What was the clinical indication for this 
treatment? (n=1926)  (n=1851)  
Severe perianal CD 15% (297)  9% (157)  
Active luminal CD 81% (1560)  88% (1625)  
Fistulating CD 1% (22)  0.5% (10)  
Other clinical indication 2% (29)  1% (21)  
Not known 1% (19)  2% (38)  
Dose given at this infusion (mg/kg) (n=1594)    
5  100% (1590)  NA NA 
10  0.3% (4)  NA NA 
Duration of infusion (mins) (n=1105)    
30 0.3% (3)  NA NA 
60 0.7% (8)  NA NA 
120 95% (1054)  NA NA 
180 3% (37)  NA NA 
240 0.2% (2)  NA NA 
Other 0.1% (1)  NA NA 
Infusion completion outcome (n=1528)  
Completed successfully at prescribed rate 98% (1492)  NA NA 
Completed successfully at lower rate 0.9% (13)  NA NA 
Restart infusion at lower rate and 
discontinued 0.2% (3)  NA NA 
Infusion discontinued and not restarted 1% (19)  NA NA 
Other 0.1% (1)  NA NA 
CD = Crohn’s disease; IQR = interquartile range; NA = not applicable; TNFα = tumour necrosis factor alpha. 
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CD: initial treatment 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=2006) 
YOUR SITE National 
(n=1894) 
YOUR SITE 
Treatment details continued 
Induction dose (mg) (n=1870)  
160/80 NA NA 80% (1492)  
80/40 NA NA 18% (342)  
Other NA NA 2% (36)  
Planned maintenance dose (mg) (n=1662)  
40 mg every other week NA NA 95% (1573)  
40 mg every week NA NA 5% (74)  
Other NA NA 0.9% (15)  
Were any adverse events recorded for this treatment? 
Yes 3% (58)  3% (48)  
Which adverse events? (more than one may have been selected) 
Abdominal pain 0.1% (1)  0.1% (1)  
Angioedema of upper airway 0.1% (2)  0.1% (1)  
Arthralgia 0.5% (9)  0.2% (3)  
Blood abnormality 0% (0)  0.1% (1)  
Bronchospasm (cough/wheeze/dyspnoea) 0.5% (10)  0.1% (1)  
Chest pain 0.1% (3)  0.1% (1)  
Chills 0% (0)  0.1% (2)  
Confirmed demyelination 0% (0)  0.1% (2)  
Dizziness 0.2% (4)  0.3% (5)  
Fatigue 0.1% (2)  0.1% (2)  
Fever 0.3% (6)  0.1% (2)  
Flushing 0.6% (12)  0% (0)  
Headache 0.6% (13)  0.3% (6)  
Hypotension 0.1% (2)  0.1% (1)  
Infection 0.1% (1)  0.2% (3)  
Injection site reaction 0% (0)  0.2% (4)  
Itching 0.4% (8)  0.2% (3)  
Nausea 0.3% (6)  0.5% (9)  
Panic attacks 0.1% (1)  0% (0)  
Rash 0.5% (9)  0.5% (9)  
Serum sickness-like reaction 0% (0)  0% (0)  
Urticaria 0.1% (2)  0% (0)  
Other 0.4% (8)  0.2% (4)  
CD = Crohn’s disease; NA = not applicable. 
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CD: initial treatment 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=2006) 
YOUR SITE National 
(n=1894) 
YOUR SITE 
Treatment details continued 
Is the patient receiving any concomitant 
therapies for the management of IBD at the 
time of this treatment? 
(n=1528) (n=1552) 
Yes 75% (1140)  72% (1120)  
If yes, indicate which concomitant therapies (more than one may have been selected) 
Allopurinol 0.3% (4)  0.1% (1)  
Azathioprine/mercaptopurine 51% (772)  45% (701)  
5-aminosalicylic acid 20% (300)  17% (267)  
Antibiotics 2% (28)  1% (16)  
Ciclosporin 0.1% (2)  0% (0)  
Dietary therapy 3% (42)  2% (36)  
Methotrexate 4% (62)  7% (113)  
Mycophenolate 0.1% (2)  0% (0)  
Steroids 27% (412)  26% (407)  
Other 1% (16)  2% (25)  
Has the patient failed to respond or are they 
intolerant to immunosuppressive drugs / 
corticosteroids? 
(n=2006) (n=1894) 
Yes 62% (1250)  69% (1313)  
If yes, indicate which previous therapies (more than one may have been selected) 
Allopurinol 0.1% (2)  0% (0)  
Azathioprine/mercaptopurine 42% (835)  49% (933)  
5-aminosalicylic acid 16% (324)  17% (326)  
Antibiotics 7% (145)  6% (104)  
Anti-TNFα 4% (82)  10% (183)  
Ciclosporin 0.2% (4)  0.1% (2)  
Dietary therapy 5% (100)  4% (84)  
Methotrexate 6% (115)  9% (162)  
Mycophenolate 0.1% (3)  0.1% (2)  
Steroids 30% (606)  29% (547)  
Tacrolimus 0.1% (1)  0.1% (1)  
Topical 0% (0)  0.1% (1)  
Ustekinumab 0% (0)  0.1% (1)  
Other 0.7% (14)  0.8% (16)  
CD = Crohn’s disease; IBD = inflammatory bowel disease; TNFα = tumour necrosis factor alpha. 
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CD: initial treatment 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=2006) 
YOUR SITE National 
(n=1894) 
YOUR SITE 
Disease severity score 
Severity of disease (n=1107)  (n=1160)  
Mild 7% (75)  6% (67)  
Moderate 43% (480)  45% (526)  
Severe 50% (552)  49% (567)  
CD = Crohn’s disease. 
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Crohn’s disease follow-up treatment at 3 months 
 
CD: follow-up treatment at 3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=818) 
YOUR SITE National 
(n=525) 
YOUR SITE 
Follow-up treatment details 
Infliximab dose given (mg/kg) (n=803)  
5 99% (795)  NA NA 
10 0.4% (3)  NA NA 
Other 0.6% (5)  NA NA 
Review of treatment plan     
Continue treatment 94% (772)  89% (467)  
Stop treatment 6% (46)  11% (58)  
If treatment was stopped, what were the 
reasons for stopping? (n=46) (n=58) 
Treatment effective and discontinued 2% (1)  0% (0)  
Loss of response 11% (5)  17% (10)  
Poor response 37% (17)  31% (18)  
Side effects / adverse events 33% (15)  41% (24)  
Patient became pregnant since initiating  
anti-TNFα treatment 0% (0)  2% (1)  
Patient choice 11% (5)  5% (3)  
Other 7% (3)  3% (2)  
If continuing adalimumab treatment, 
planned continued treatment frequency?  (n=453) 
Every week NA NA 5% (21)  
Every other week NA NA 95% (432)  
If continuing adalimumab treatment, 
planned continued treatment dose (mg)  (n=467) 
40 NA NA 99% (461)  
80 NA NA 1% (6)  
Did the patient report complete compliance 
with the maintenance regime since the last 
adalimumab review? 
 (n=440) 
Yes NA NA 95% (419)  
No NA NA 5% (21)  
If incomplete compliance, state reason 
(more than one may have been selected)  (n=21) 
Number of missed doses NA NA 14% (3)  
Increased interval between doses NA NA 14% (3)  
Patient missed out some treatment weeks NA NA 38% (8)  
Patient stopped treatment NA NA 19% (4)  
Compliance affected due to interventions in 
treatment NA NA 10% (2)  
Other compliance difference NA NA 10% (2)  
CD = Crohn’s disease; NA = not applicable; TNFα = tumour necrosis factor alpha. 
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CD: follow-up treatment at 3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=818) 
YOUR SITE National 
(n=525) 
YOUR SITE 
Follow-up treatment details continued 
Were there any adverse events since the last review? 
Yes 6% (51)  11% (57)  
What adverse events? (more than one may have been selected) 
Abdominal pain 0.1% (1)  0.4% (2)  
Alopecia 0% (0)  0.2% (1)  
Angioedema of upper airway 0.1% (1)  0% (0)  
Arthralgia 0.6% (5)  1% (5)  
Blood abnormality 0.2% (2)  0.8% (4)  
Bronchospasm (cough/wheeze/dyspnoea) 0.4% (3)  0.2% (1)  
Cardiac failure 0.1% (1)  0% (0)  
Chest pain 0.1% (1)  0% (0)  
Chills 0.1% (1)  0% (0)  
Death 0.1% (1)  0% (0)  
Difficulty breathing 0.2% (2)  0.2% (1)  
Dizziness 0.4% (3)  0.2% (1)  
Fatigue 0.1% (1)  0.6% (3)  
Fever 0.1% (1)  0.4% (2)  
Flushing 0.6% (5)  0.2% (1)  
Headache 0.5% (4)  0% (0)  
Hypotension 0.1% (1)  0.2% (1)  
Infection 2% (13)  0.2% (1)  
Injection site reaction 0% (0)  0.6% (3)  
Itching 0.1% (1)  0.6% (3)  
Nausea 0.6% (5)  1% (5)  
Rash 0.9% (7)  3% (13)  
Urticaria 0% (0)  0.6% (3)  
Other 2% (12)  2% (10)  
CD = Crohn’s disease; NA = not applicable. 
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CD: follow-up treatment at 3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=818) 
YOUR SITE National 
(n=525) 
YOUR SITE 
Follow-up treatment details continued 
Is the patient currently receiving any other 
therapies for the management of IBD?  (n=554) (n=446) 
Yes 63% (351)  55% (246)  
If yes, indicate which other therapies (more than one may have been selected) 
Allopurinol 0.2% (1)  0% (0)  
Azathioprine/mercaptopurine 50% (277)  35% (156)  
Methotrexate 4% (20)  6% (27)  
Steroids 4% (23)  9% (41)  
5-aminosalicylic acid 17% (92)  10% (46)  
Antibiotics 0% (0)  0.4% (2)  
Dietary therapy 1% (6)  2% (9)  
Topical 0% (0)  0.2% (1)  
Other 0.7% (4)  3% (13)  
Disease severity score 
Severity of disease (n=363)  (n=321)  
Mild 54% (195)  48% (153)   
Moderate 29% (104)  37% (120)  
Severe 18% (64)  15% (48)  
CD = Crohn’s disease; IBD = inflammatory bowel disease; NA = not applicable. 
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Crohn’s disease follow-up treatment at 12 months 
 
CD: follow-up treatment at 
12 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=339) 
YOUR SITE National 
(n=181) 
YOUR SITE 
Follow-up treatment details 
Infliximab dose given at this treatment 
(mg/kg) (n=334)  
5 97% (323)  NA NA 
10 3% (9)  NA NA 
Other 0.6% (2)  NA NA 
Review of treatment plan 
Continue treatment 93% (314)  88% (159)  
Stop treatment 7% (25)  12% (22)  
If treatment was stopped, what were the 
reasons for stopping? (n=25) (n=22) 
Loss of response 16% (4)  9% (2)  
Treatment effective and discontinued 40% (10)  27% (6)  
Side effects / adverse events 20% (5)  27% (6)  
Funding 4% (1)  5% (1)  
Poor response 4% (1)  9% (2)  
Patient choice 4% (1)  9% (2)  
Patient became pregnant since initiating  
anti-TNFα treatment 4% (1)  9% (2)  
Other 4% (1)  5% (1)  
If continuing adalimumab treatment, 
planned continued treatment frequency  (n=154) 
Every week NA NA 12% (19)  
Every other week NA NA 86% (133)  
Other NA NA 1% (2)  
If continuing adalimumab treatment, 
planned continued treatment dose (mg)  (n=158) 
20/25 NA NA 0.6% (1)  
30 NA NA 0.6% (1)  
40 NA NA 96% (152)  
80 NA NA 3% (4)  
Did the patient report complete compliance 
with the maintenance regime since the last 
adalimumab review? 
 (n=157) 
Yes NA NA 93% (146)  
No NA NA 7% (11)  
CD = Crohn’s disease; NA = not applicable; TNFα = tumour necrosis factor alpha. 
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CD: follow-up treatment at 
12 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=339) 
YOUR SITE National 
(n=181) 
YOUR SITE 
Follow-up treatment details continued 
If incomplete compliance, state reason  
(more than one may have been selected)  (n=11) 
Number of missed doses NA NA 36% (4)  
Patient missed out some treatment weeks NA NA 36% (4)  
Patient stopped treatment NA NA 27% (3)  
Were there any adverse events since the last review? 
Yes 6% (20)  6% (11)  
What adverse events? (more than one may have been selected) 
Abdominal pain 0% (0)  0.6% (1)  
Alopecia 0.3% (1)  0% (0)  
Angioedema of upper airway 0% (0)  0.6% (1)  
Bronchospasm (cough/wheeze/dyspnoea) 0.6% (2)  0.6% (1)  
Chills 1% (4)  0.6% (1)  
Fatigue 0% (0)  0.6% (1)  
Flushing 0.3% (1)  0% (0)  
Headache 0.3% (1)  0.6% (1)  
Infection 3% (9)  1% (2)  
Itching 0.3% (1)  0% (0)  
Malignancy 0.3% (1)  0% (0)  
Rash 0.3% (1)  0.6% (1)  
Serum sickness-like reaction 0.3% (1)  0% (0)  
Other 2% (5)  2% (4)  
Is the patient currently receiving any other 
therapies for the management of IBD?  (n=247)  (n=157)  
Yes 58% (143)  59% (93)  
If yes, indicate which other therapies (more than one may have been selected) 
Allopurinol 0.4% (1)  0% (0)  
Azathioprine/mercaptopurine 45% (112)  40% (62)  
5-aminosalicylic acid 14% (34)  12% (18)  
Antibiotics 0% (0)  0.6% (1)  
Dietary therapy 0.4% (1)  0% (0)  
Methotrexate 3% (7)  7% (11)  
Mycophenolate 0% (0)  0% (0)  
Steroids 2% (6)  10% (15)  
Other 1% (3)  3% (5)  
CD = Crohn’s disease; IBD = inflammatory bowel disease; NA = not applicable. 
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CD: follow-up treatment at 
12 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=339) 
YOUR SITE National 
(n=181) 
YOUR SITE 
Disease severity score 
Severity of disease (n=193)  (n=140)  
Remission 0% (0)  0.7% (1)  
Mild 60% (116)  58% (81)  
Moderate 25% (49)  30% (42)  
Severe 15% (28)  11% (16)  
CD = Crohn’s disease. 
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Ulcerative colitis disease details 
 
UC: disease details  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=633) 
National 
(n=83) 
Diagnosis 
Maximal disease distribution at the time of 
decision to initiate biological therapy, as 
defined by the Montreal classification 
(n=632)  
Proctitis (E1) 10% (61) 6% (5) 
Left sided (E2) 45% (284) 37% (31) 
Extensive (E3) 45% (287) 57% (47) 
Time between date of diagnosis and date of 
initial treatment (n=630) (n=81) 
<1 year ago 31% (195) 16% (13) 
1–2 years ago 22% (139) 30% (24) 
3–5 years ago 16% (101) 26% (21) 
6–10 years ago 15% (97) 14% (11) 
>10 years ago 16% (98) 15% (12) 
UC = ulcerative colitis. 
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Ulcerative colitis initial treatment 
 
UC: initial treatment  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=633) 
National 
(n=83) 
Consent 
Was informed consent to receive anti-TNFα treatment taken from this patient? 
Yes 99% (624) 100% (83) 
No 1% (9) 0% (0) 
If yes, was this verbal or written?  (n=624)    
Verbal 79% (495) 80% (66) 
Written 21% (129) 21% (17) 
Treatment details 
Time between date of decision to start and date of initial treatment (first loading dose) 
Median (IQR) time (days) 5 (1,17) 23 (10, 45) 
What was the clinical indication for this 
treatment? (n=632)   
Acute severe UC 69% (436) 40% (33) 
Chronic refractory UC 28% (179) 53% (44) 
Other clinical indication 1% (7) 4% (3) 
Not known 2% (10) 4% (3) 
Dose given at this infusion (mg/kg) (n=485) 
5 100% (484) NA 
10 0.2% (1) NA 
Duration of infusion (mins) (n=476) 
60 2% (7) NA 
120 96% (457) NA 
180 3% (12) NA 
Infusion completion outcome 
Completed successfully at prescribed rate 98% (622) NA 
Completed successfully at lower rate 0.8% (5) NA 
Infusion discontinued and not restarted 0.8% (5) NA 
Other 0.2% (1) NA 
Induction dose (mg) 
160/80 NA 89% (74) 
80/40 NA 10% (8) 
Other NA 1% (1) 
Planned maintenance dose 
40 mg every other week NA 94% (78) 
40 mg every week NA 6% (5) 
IQR = interquartile range; NA = not applicable; TNFα = tumour necrosis factor alpha; UC = ulcerative colitis. 
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UC: initial treatment 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=633) 
National 
(n=83) 
Treatment details continued 
Were any adverse events recorded for this treatment? 
Yes 2% (10) 1% (1) 
Which acute reactions? (more than one may have been selected) 
Arthralgia 0.2% (1) 0% (0) 
Bronchospasm (cough/wheeze/dyspnoea) 0.3% (2) 0% (0) 
Chest pain 0.2% (1) 0% (0) 
Dizziness 0.5% (3) 0% (0) 
Fatigue 0.2% (1) 0% (0) 
Hypotension 0.3% (2) 0% (0) 
Itching 0.2% (1) 0% (0) 
Nausea 0.3% (2) 0% (0) 
Other 0.5% (3) 1% (1) 
Is the patient receiving any concomitant therapies for the management of IBD at the time of this treatment?  
Yes 89% (561) 87% (72) 
If yes, indicate which concomitant therapies (more than one may have been selected) 
Allopurinol 0.2% (1) 0% (0) 
Azathioprine/mercaptopurine 46% (288) 42% (35) 
5-aminosalicylic acid 46% (293) 48% (40) 
Antibiotics 2% (12) 2% (2) 
Dietary therapy 0.6% (4) 0% (0) 
Methotrexate 4% (22) 5% (4) 
Mycophenolate 0.8% (5) 0% (0) 
Steroids 54% (344) 42% (35) 
Tacrolimus 0.3% (2) 0% (0) 
Topical 0% (0) 1% (1) 
Other 2% (11) 1% (1) 
IBD = inflammatory bowel disease; UC = ulcerative colitis. 
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UC: initial treatment  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=633) 
National 
(n=83) 
Treatment details continued 
Has the patient failed to respond or are they intolerant to immunosuppressive drugs / corticosteroids? 
Yes 64% (403) 78% (65) 
If yes, indicate which previous therapies (more than one therapy may have been selected) 
Azathioprine/mercaptopurine  41% (260) 63% (52) 
5-aminosalicylic acid 25% (155) 28% (23) 
Antibiotics 0.6% (4) 0% (0) 
Anti-TNFα  1% (7) 21% (17) 
Ciclosporin 1% (7) 1% (1) 
Methotrexate 5% (29) 12% (10) 
Steroids 34% (218) 22% (18) 
Tacrolimus 0.3% (2) 1% (1) 
Other 0.3% (2) 1% (1) 
Disease severity score 
Severity of disease (n=513) (n=71) 
Mild 4% (19) 3% (2) 
Moderate 24% (125) 42% (30) 
Severe 72% (369) 55% (39) 
TNFα = tumour necrosis factor alpha; UC = ulcerative colitis. 
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Ulcerative colitis follow-up treatment at 3 months 
 
UC: follow-up treatment at 3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=157) 
National 
(n=19) 
Follow-up treatment details 
Infliximab dose given at this treatment (mg/kg) 
5 99% (155) NA 
10 0.6% (1) NA 
Other 0.6% (1) NA 
Review of treatment plan     
Continue treatment 82% (128) 74% (14) 
Stop treatment 19% (29) 26% (5) 
If treatment was stopped, what were the 
reasons for stopping? (n=29) (n=5) 
Treatment effective and discontinued 41% (12) 0% (0) 
Loss of response 3% (1) 20% (1) 
Poor response 17% (5) 60% (3) 
Side effects / adverse events 28% (8) 20% (1) 
Funding 7% (2) 0% (0) 
Other 3% (1) 0% (0) 
If continuing adalimumab treatment, 
planned continued treatment frequency  (n=14) 
Every week NA 7% (1) 
Every other week NA 93% (13) 
If continuing adalimumab treatment, 
planned continued treatment dose (mg)  (n=14) 
80 NA 7% (1) 
40 NA 93% (13) 
Did the patient report complete compliance with the maintenance regime since the last adalimumab review? 
Yes NA 90% (17) 
No NA 11% (2) 
If incomplete compliance, state reason  (n=2) 
Patient missed out some treatment weeks NA 50% (1) 
Other compliance difference NA 50% (1) 
NA = not applicable; UC = ulcerative colitis. 
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UC: follow-up treatment at 3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=157) 
National 
(n=19) 
Follow-up treatment details continued 
Were there any adverse events since the last review?  
Yes 9% (14) 16% (3) 
What adverse events? (more than one may have been selected) 
Abdominal pain 1% (2) 0% (0) 
Angioedema of upper airway 0.6% (1) 0% (0) 
Blood abnormality 0.6% (1) 0% (0) 
Bronchospasm (cough/wheeze/dyspnoea) 2% (3) 0% (0) 
Dizziness 0% (0) 5% (1) 
Fatigue 0% (0) 5% (1) 
Flushing 3% (4) 5% (1) 
Headache 1% (2) 0% (0) 
Hypotension 1% (2) 0% (0) 
Infection 3% (5) 11% (2) 
Itching 0.6% (1) 0% (0) 
Nausea 0.6% (1) 0% (0) 
Rash 0.6% (1) 0% (0) 
Suspected demyelination 0.6% (1) 0% (0) 
Urticaria 0.6% (1) 0% (0) 
Other 0.6% (1) 5% (1) 
Is the patient currently receiving any other therapies for the management of IBD? 
Yes 74% (116) 79% (15) 
If yes, indicate which other therapies (more than one may have been selected) 
Allopurinol 0.6% (1) 0% (0) 
Azathioprine/mercaptopurine 55% (87) 16% (3) 
Methotrexate 1% (2) 5% (1) 
Steroids 7% (11) 16% (3) 
5-aminosalicylic acid 32% (50) 53% (10) 
Other 0.6% (1) 0% (0) 
Disease severity score 
Severity of disease (n=128) (n=15) 
Mild  56% (71) 47% (7) 
Moderate 28% (36) 13% (2) 
Severe 16% (21) 40% (6) 
IBD = inflammatory bowel disease; UC = ulcerative colitis. 
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Ulcerative colitis follow-up treatment at 12 months 
 
UC: follow-up treatment at 
12 months 
 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=49) 
National 
(n=3) 
Follow-up treatment details 
Infliximab dose given at this treatment (mg/kg) 
5 96% (47) NA 
10 2% (1) NA 
Other 2% (1) NA 
Review of treatment plan     
Continue treatment 94% (46) 67% (2) 
Stop treatment 6% (3) 33% (1) 
If treatment was stopped, what were the 
reasons for stopping? (n=3) (n=1) 
Treatment effective and discontinued 33% (1) 100% (1) 
Side effects / adverse events 33% (1) 0% (0) 
Funding 33% (1) 0% (0) 
If continuing adalimumab treatment, 
planned continued treatment frequency  (n=2) 
Every other week NA 100% (2) 
If continuing adalimumab treatment, 
planned continued treatment dose (mg)  (n=2) 
40 NA 100% (2) 
Did the patient report complete compliance with the maintenance regime since the last adalimumab review? 
Yes NA 100% (3) 
Were there any adverse events since the last review?  
Yes 2% (1) 33% (1) 
What adverse events? (more than one may have been selected) 
Nausea 2% (1) 0% (0) 
Other 0% (0) 33% (1) 
Is the patient currently receiving any other therapies for the management of IBD? 
Yes 86% (42) 100% (3) 
If yes, indicate which other therapies (more than one may have been selected) 
Azathioprine/mercaptopurine 59% (29) 67% (2) 
5-aminosalicylic acid 51% (25) 33% (1) 
Methotrexate 6% (3) 33% (1) 
Steroids 2% (1) 33% (1) 
Other 2% (1) 0% (0) 
IBD = inflammatory bowel disease; NA = not applicable; UC = ulcerative colitis. 
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UC: follow-up treatment at 
12 months  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=49) 
National 
(n=3) 
Disease severity score 
Severity of disease (n=43) (n=2) 
Mild  51% (22) 100% (2) 
Moderate 33% (14) 0% (0) 
Severe 16% (7) 0% (0) 
UC = ulcerative colitis. 
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Inflammatory bowel disease type unclassified disease details 
 
IBDU: disease details  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=78) 
National 
(n=24) 
Diagnosis 
Maximal disease distribution at the time of decision to initiate biological therapy, as defined by the Montreal 
classification 
Proctitis (E1) 1% (1) 4% (1) 
Left sided (E2) 44% (34) 54% (13) 
Extensive (E3) 55% (43) 42% (10) 
Time between date of diagnosis and date of initial treatment 
<1 year 39% (30) 13% (3) 
1–2 years 28% (22) 25% (6) 
3–5 years 21% (16) 25% (6) 
6–10 years 5% (4) 8% (2) 
>10 years 8% (6) 29% (7) 
IBDU = inflammatory bowel disease type unclassified. 
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Inflammatory bowel disease type unclassified initial treatment 
 
IBDU: initial treatment  
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=78) 
National 
(n=24) 
Consent 
Was informed consent to receive anti-TNFα treatment taken from this patient? 
Yes 99% (77) 100% (24) 
No 1% (1) 0% (0) 
If yes, was this verbal or written?  (n=77)  
Verbal 71% (55) 92% (22) 
Written 29% (22) 8% (2) 
Treatment details 
Time between date of decision to start and date of initial treatment (first loading dose) 
Median (IQR), days 9 (2, 21) 15 (4, 30) 
What was the clinical indication for this 
treatment? (n=77)  
Acute severe IBDU 66% (51) 46% (11) 
Chronic refractory IBDU 34% (26) 50 (12) 
Other clinical indication 3% (2) 4% (1) 
Dose given at this infusion (mg/kg) (n=64) 
5 98% (63) NA 
10 2% (1) NA 
Duration of infusion (mins)  (n=63) 
120 97% (61) NA 
180 3% (2) NA 
Infusion completion outcome 
Completed successfully at prescribed rate 97% (76) NA 
Infusion discontinued and not restarted 1% (1) NA 
Other 1% (1) NA 
Induction dose (mg) 
160/80 NA 63% (15) 
80/40 NA 38% (9) 
Planned maintenance dose 
40 mg every other week NA 92% (22) 
40 mg every week NA 8% (2) 
Were any adverse events recorded for this treatment? 
Yes 0% (0) 0% (0) 
IBDU = inflammatory bowel disease type unclassified; IQR = interquartile range; NA = not applicable; TNFα = tumour necrosis 
factor alpha. 
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IBDU: initial treatment 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=78) 
National 
(n=24) 
Treatment details continued 
Is the patient receiving any concomitant therapies for the management of IBD at the time of this treatment?  
Yes 92% (72) 88% (21) 
If yes, indicate which concomitant therapies (more than one may have been selected) 
Allopurinol 0% (0) 4% (1) 
Azathioprine/mercaptopurine 41% (32) 63% (15) 
Methotrexate 3% (2) 8% (2) 
Steroids 59% (46) 42% (10) 
5-aminosalicylic acid 55% (43) 46% (11) 
Antibiotics 1% (1) 0% (0) 
Has the patient failed to respond or are they intolerant to immunosuppressive drugs / corticosteroids? 
Yes 65% (51) 67% (16) 
If yes, indicate which previous therapies (more than one may have been selected) 
Azathioprine/mercaptopurine 41% (32) 46% (11) 
Methotrexate 8% (6) 8% (2) 
Steroids 27% (21) 29% (7) 
Anti-TNFα 1% (1) 25% (6) 
5-aminosalicylic acid 22% (17) 25% (6) 
Ciclosporin 4% (3) 0% (0) 
Disease severity score 
Severity of disease (n=50) (n=12) 
Mild 8% (4) 0% (0) 
Moderate 36% (18) 75% (9) 
Severe 56% (28) 25% (3) 
IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease type unclassified; TNFα = tumour necrosis factor alpha. 
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Inflammatory bowel disease type unclassified follow-up treatment at 3 months 
 
IBDU: follow-up treatment at 
3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=30) 
National 
(n=12) 
Follow-up treatment details 
Infliximab dose given at this treatment (mg/kg) 
5 100% (30) NA 
Review of treatment plan 
Continue treatment 93% (28) 92% (11) 
Stop treatment 7% (2) 8% (1) 
If treatment was stopped, what were the 
reasons for stopping? (n=2) (n=1) 
Poor response 0% (0) 100% (1) 
Side effects / adverse events 50% (1) 0% (0) 
Other 50% (1) 0% (0) 
If continuing adalimumab treatment, 
planned continued treatment frequency  (n=11) 
Every other week NA 100% (11) 
If continuing adalimumab treatment, 
planned continued treatment dose (mg)  (n=11) 
40 NA 100% (11) 
Did the patient report complete compliance with the maintenance regime since the last adalimumab review? 
Yes NA 100% (12) 
Did the patient report any adverse events?     
Yes 3% (1) 0% (0) 
Which adverse events? (more than one may have been selected) 
Bronchospasm (cough/wheeze/dyspnoea) 3% (1) 0% (0) 
Dizziness 3% (1) 0% (0) 
Panic attacks 3% (1) 0% (0) 
Is the patient currently receiving any other therapies for the management of IBD?  
Yes 77% (23) 75% (9) 
If yes, indicate which other therapies (more than one may have been selected) 
Azathioprine/mercaptopurine 57% (17) 67% (8) 
Steroids 17% (5) 17% (2) 
5-aminosalicylic acid 50% (15) 25% (3) 
IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease type unclassified; NA = not applicable. 
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IBDU: follow-up treatment at 
3 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=30) 
National 
(n=12) 
Disease severity score 
Severity of disease (n=18)  (n=5)  
Mild  56% (10) 40% (2) 
Moderate 33% (6) 40% (2) 
Severe 11% (2) 20% (1) 
IBDU = inflammatory bowel disease type unclassified. 
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Inflammatory bowel disease type unclassified follow-up treatment at 12 months 
 
IBDU: follow-up treatment  
at 12 months 
Frequency (%, n) 
Infliximab Adalimumab 
National 
(n=12) 
National 
(n=2) 
Follow-up treatment details 
Infliximab dose given at this treatment (mg/kg) 
5 100% (12) NA 
Review of treatment plan 
Continue treatment 83% (10) 50% (1) 
Stop treatment 17% (2) 50% (1) 
If treatment was stopped, what were the 
reasons for stopping? (n=2) (n=1) 
Loss of response 50% (1) 0% (0) 
Treatment effective and discontinued 50% (1) 100% (1) 
If continuing adalimumab treatment, 
planned continued treatment frequency  (n=1) 
Every week NA 100% (1) 
If continuing adalimumab treatment, 
planned continued treatment dose (mg)  (n=1) 
40 NA 100% (1) 
Did the patient report complete compliance with the maintenance regime since the last adalimumab review? 
Yes NA 100% (2) 
Did the patient report any adverse events?     
Yes 0% (0) 0% (0) 
Is the patient currently receiving any other therapies for the management of IBD?  
Yes 58% (7) 100% (2) 
If yes, indicate which other therapies (more than one may have been selected) 
Azathioprine/mercaptopurine 42% (5) 100% (2) 
5-aminosalicylic acid 33% (4) 0% (0) 
Steroids 8% (1) 50% (1) 
Disease severity score 
Severity of disease (n=10)  (n=1)  
Mild  80% (8) 100% (1) 
Moderate 20% (2) 0% (0) 
IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease type unclassified. 
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IBD-related surgery 
Of the analysed adult patients, 1241 had one or more surgical procedures related to their IBD. The 
surgery performed on these patients is categorised according to whether it was carried out before or 
after biological therapies were started. Only surgeries for patients included in the national analysis are 
presented in tables 18–20. One table is given for each disease type.  
 
Table 18 Surgical procedures in adult patients with CD 
CD-related surgery 
Adult patients with surgery recorded 
(n=1151) 
Before starting  
biological therapy 
(n=1034)* 
After starting biological 
therapy 
 (n=200)* 
Surgical procedure by type (%, n) 
Anterior resection 0.3% (3) 0% (0) 
Appendicectomy 2% (15) 0% (0) 
Cholecystectomy 1% (11) 0% (0) 
Colectomy and ileostomy 6% (62) 8% (15) 
Drainage of abscess 3% (30) 3% (5) 
Excision of fistula 2% (15) 0% (0) 
Gastric surgery 0.1% (1) 0.5% (1) 
Other surgical procedure 22% (226) 25% (50) 
Partial colectomy 5% (48) 2% (4) 
Perianal surgery 23% (238) 24% (47) 
Proctectomy 0.3% (3) 0% (0) 
Right hemicolectomy / ileocaecal resection 42% (431) 16% (31) 
Small bowel resection 22% (225) 22% (44) 
Stoma formation 2% (21) 0.5% (1) 
Stricturoplasty 4% (43) 4% (8) 
Total colectomy with ileorectal anastomosis 0.4% (4) 0% (0) 
Total proctocolectomy ileoanal pouch 1% (14) 0% (0) 
Total proctocolectomy permanent ileostomy 3 (31) 4 (8) 
*Patients may have one or more surgeries recorded. 
CD = Crohn’s disease. 
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Table 19 Surgical procedures in adult patients with UC  
UC-related surgery 
Adult patients with surgery recorded 
(n=78) 
Before starting  
biological therapy  
(n=26)* 
After starting biological 
therapy 
 (n=54)* 
Surgical procedure by type (%, n)  
Appendicectomy 4% (1) 0% (0) 
Colectomy and ileostomy 46% (12) 74% (40) 
Other surgical procedure 35% (9) 6% (3) 
Partial colectomy 4% (1) 4% (2) 
Perianal surgery 15% (4) 6% (3) 
Right hemicolectomy / ileocaecal resection 4% (1) 0% (0) 
Small bowel resection 4% (1) 0% (0) 
Total proctocolectomy ileoanal pouch 15% (4) 4% (2) 
Total proctocolectomy permanent ileostomy 0% (0) 9% (5) 
*Patients may have one or more surgeries recorded. 
UC = ulcerative colitis. 
 
 
Table 20 Surgical procedures in adult patients with IBDU 
IBDU-related surgery 
Adult patients with surgery recorded 
(n=12) 
Before starting  
biological therapy  
(n=6)* 
Before starting  
biological therapy  
(n=7)* 
Surgical procedure by type (%, n) 
Colectomy and ileostomy 17% (1) 71% (5) 
Perianal surgery 67% (4) 14% (1) 
Total proctocolectomy ileoanal pouch 17% (1) 14% (1) 
*Patients may have one or more surgeries recorded. 
IBDU = inflammatory bowel disease type unclassified. 
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Patient-reported outcome measures (PROMs) 
Outcome measures have traditionally relied on disease activity indexes, but these measures fail to 
assess the patient’s subjective view of their experience. Patient-reported outcome measures therefore 
evaluate quality from the patient’s perspective. Typically, they are short, self-completed questionnaires 
that measure the patient’s health status or health-related quality of life at a single point in time. The 
health status information is collected from patients by way of PROMs questionnaires completed before, 
during and after an intervention (in this case, initiation of biological therapy) and provides an indication 
of the outcomes or quality of care delivered to patients. 
 
EQ-5D 
The EQ-5D is a standardised instrument for use as a measure of health outcome. It provides a simple 
descriptive profile and a single index value for health status. It was primarily designed for self-
completion by respondents and is ideally suited for use in clinics.  
 
The EQ-5D is a descriptive system of health-related quality of life states consisting of five dimensions 
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each of which can take 
one of three responses depending on level of severity – no problems / some or moderate problems / 
extreme problems – within a particular EQ-5D dimension. Total EQ-5D scores range from 0 (worst health 
/ death) to 1 (best health), with an increase in score denoting improved health. Scores from each 
domain are weighted and converted into a single weighted summary index. The data within this report 
are presented in the form of a median (IQR). The EQ-5D has been shown to be valid, reliable and 
responsive in patients with IBD.15 
 
In total, 1416 EQ-5D questionnaires were completed at an initial treatment for patients taking infliximab 
and adalimumab and for all disease types, with a median (IQR) score of 0.76 (0.66, 0.85). At 3-month 
follow-up, 361 EQ-5D questionnaires were completed for patients taking infliximab and adalimumab and 
for all disease types, with a median (IQR) score of 0.80 (0.73, 1.0). At 12-month follow-up, 57 EQ-5D 
questionnaires were completed for patients taking infliximab and adalimumab and for all disease types, 
with a median (IQR) score of 0.80 (0.69, 1.0). 
 
The limited number of patients with EQ-5D scores at initial and follow-up treatment means that the 
difference between the EQ-5D scores at these timepoints could not be calculated. However, the median 
scores at these two stages was calculated for all patients who had a score; comparison of these medians 
showed an increase in the median EQ-5D score of 0.04 between initial and 3-month follow-up 
treatment. This may suggest a clinical improvement in quality of life after patients started biological 
therapies.  
 
CUCQ-12 
The CUCQ-12 is a relatively new and shortened version of the 32-item Crohn’s and Colitis Questionnaire 
(CCQ-32) – a quality of life measurement tool developed specifically for use with patients with IBD to 
measure active disease and long-term monitoring of the condition.  
 
The items in the CUCQ-12 questionnaire address the following 12 dimensions: sleeping, appetite, energy 
level, rushing to the toilet, being bloated, incomplete emptying of bowels, blood in stool, generally 
unwell, faecal incontinence, nocturnal diarrhoea, passing wind and effect on leisure activity. Each 
question is scored between 0 (best health) and 14 (poor health), corresponding to the number of days 
affected by a parameter in a fortnight, giving a total CUCQ-12 score ranging from 0 (best health) to 168 
(poor health). Remission in patients with UC and CD is suggested by CUCQ-12 scores of <45 and <50, 
respectively. The minimum significant change in CUCQ-12 is 13 for both UC and CD. Early results have 
shown that the CUCQ-12 performs well in patients with IBD, with positive correlations compared with 
the EQ-5D and 12-item short-form (SF-12). 
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In total, 1256 CUCQ-12 questionnaires were completed at initial treatment for patients taking infliximab 
and adalimumab and for all disease types. The median (IQR) score of 68 (39, 100) suggests active IBD at 
this timepoint. At follow-up treatment, 332 questionnaires were completed for patients taking 
infliximab and adalimumab and for all disease types. The median (IQR) score was 34 (14, 60). 
 
The limited number of patients with CUCQ-12 scores at initial and follow-up treatment means that the 
difference between the CUCQ-12 scores at these timepoints could not be calculated. However, the 
median scores at these two stages could be calculated for all patients who had a score; comparison of 
these medians showed a reduction in the median CUCQ-12 score of 34 between initial and follow-up 
treatment. This may suggest a clinically significant improvement in quality of life after starting biological 
therapies. The CUCQ-12 findings of the biological therapy audit will be used to inform learning and the 
ongoing validity assessment of this PROM tool. 
 
Table 17 from section 2 of this report is provided again for reference. 
 
Table 17 PROMs questionnaire for IBD (IBD-PROM) 
IBD-PROM Initial treatment 
 
3-month follow-
up 
12-month follow-
up 
Patients with IBD-PROM completed 
(%, n/N) 
30%  
(1416/4718) 
25%  
(384/1561) 
22%  
(129/586) 
Patients with EQ-5D data completed 
(%, n/N) 
97%  
(1367/1416) 
94%  
(361/384) 
44%  
(57/129) 
EQ-5D score, median (IQR) 0.76 (0.66, 0.85) 0.80 (0.73, 1) 0.80 (0.69, 1) 
Patients with CUCQ-12 data 
completed (%, n/N) 
89%  
(1256/1416) 
87%  
(332/384) 
87%  
(112/129) 
CUCQ-12 score, median (IQR) 68 (39, 100) 34 (14, 60) 27 (10, 49) 
CUCQ-12 = Crohn’s and ulcerative colitis questionnaire; IBD = inflammatory bowel disease; IQR = interquartile range; PROMs = 
patient-reported outcome measures. 
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6: Participation and individual site key indicator data 
 
Participation  
Since the audit’s inception, levels of participation have varied. Participation falls into one of three main 
categories: 
• Sites that have been entering data, which are known as participating sites (or participants), 
which can be broken down into three further categories: 
- Those that have entered data regularly over the past year of data collection 
- Those that have previously entered data into the audit but have not done so during the 
past year of data collection 
- Those that have entered data but the data do not meet the audit criteria (for example, 
already established patients or unlocked submissions). 
• Sites that have never entered any data to the audit, which are known as non-participating sites 
(or non-participant).  
• Sites that do not administer biological therapies to their patients with IBD, which are known as 
not eligible.  
 
Table 21 shows the different levels of adult site participation. 
 
Table 21 Participation status for adult sites 
Participation status for adult sites Sites (n) 
Participated with regular data entry 151 
Participated but data submitted do not meet audit criteria 11 
Previously participated but no data entered during past year of data collection 32 
Not participated 20 
Not eligible to participate 2 
Total number of adult sites 216 
 
Table 22 Adult site participation status over time 
Table 22 shows participation of adult sites, trusts / health boards by country over time. Some services 
have reconfigured, so participating denominators vary. 
 
Participating site  Audit reporting dates (%, n/N) 
June 2012 August 2013 September 2014 September 2015 
England     
Sites 43% (76/177) 68% (115/169) 90% (149/165) 96% (160/166) 
Trusts 52% (75/143) 79% (106/135) 94% (133/141) 98% (134/137) 
Northern Ireland     
Sites  17% (2/12) 67% (8/12) 92% (11/12) 92% (11/12) 
Trusts  40% (2/5) 100% (5/5) 100% (5/5) 100% (5/5) 
Scotland     
Sites 44% (8/18) 67% (12/18) 55% (11/20) 62% (13/21) 
Health boards  80% (8/10) 82% (9/11) 64% (7/11) 91% (10/11) 
Wales     
Sites  41% (7/17) 39% (7/18) 60% (9/15) 67% (10/15) 
Health boards 67% (4/6) 67% (4/6) 67% (4/6) 67% (4/6) 
Total     
Sites 42% (93/224) 65% (142/217) 84% (180/214) 90% (194/216) 
Trusts / health boards 54% (89/164) 79% (124/157) 91% (149/163) 96% (153/159) 
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Key indicator data for individual sites 
This table gives named key site data in alphabetical order of participating site in England, Northern Ireland, Scotland and Wales. These key indicators were 
agreed by the IBD programme steering group as reflecting the areas of particular importance to people with IBD. An asterisk next to the name of the site in the 
table denotes that the site has taken part in PANTs. 
 
 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
England (n=167) 
Aintree University Hospitals NHS Foundation Trust 
Aintree University Hospital Participant n=22 3 (1, 8) n<6 n<6 64% (14/22) 13% (1/8) 6% (2/32) 
Airedale NHS Foundation Trust 
Airedale General Hospital* Participant n=28 2 (1, 9) 
n=26  
10 (7, 12) 60% (6/10) 20% (5/25) 18% (2/11) 45% (17/38) 
Ashford and St Peter’s Hospitals NHS Foundation Trust 
Ashford Hospital and St Peter's Hospital Participant but data submitted do not meet audit criteria 
Barking, Havering and Redbridge Hospitals NHS Trust 
King George Hospital and Queens 
Hospital combined Participant 
n=46 
5 (1, 10) 
n=22  
11 (7, 13) 71% (5/7) 59% (27/46) 4% (1/26) 0% (0/63) 
Barnsley Hospital NHS Foundation Trust 
Barnsley District General Hospital Participant n=50 3 (1, 12) n<6 n=0 43% (22/51) 4% (1/24) 0% (0/68) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Barts Health NHS Trust 
Newham University Hospital Participant n=12 2 (1, 16) n<6 n=0 50% (6/12) 0% (0/7) 0% (0/14) 
The Royal London Hospital and  
St Bartholomew’s Hospital combined Participant 
n=28 
4 (2, 10) 
n=24  
5 (1, 8) 90% (9/10) 73% (8/11) 0% (0/11) 56% (18/32) 
Whipps Cross University Hospital Participant but data submitted do not meet audit criteria 
Basildon and Thurrock University Hospitals NHS Foundation Trust 
Basildon Hospital* Participant n=24 4 (1, 15) 
n=26  
10 (6, 11) 67% (4/6) 57% (8/14) 0% (0/6) 52% (14/27) 
Blackpool Teaching Hospitals NHS Foundation Trust 
Blackpool Victoria Hospital*  Participant n=7 0 (0, 2) 
n=8  
11 (5, 13) n<6 n<6 50% (1/2) 88% (7/8) 
Bradford Teaching Hospitals Foundation Trust  
Bradford Royal Infirmary* Participant n=34 3 (1, 13) 
n=19  
5 (3, 8) 57% (4/7) 52% (12/23) 15% (2/13) 44% (18/41) 
Brighton and Sussex University Hospitals NHS Trust 
Royal Sussex County Hospital* and 
Princess Royal Hospital combined Participant 
n=39 
8 (1, 21) 
n=16  
6 (2, 10) 56% (5/9) 58% (22/38) 0% (0/17) 7% (4/56) 
Buckinghamshire Healthcare NHS Trust 
Stoke Mandeville Hospital and 
Wycombe General Hospital combined Previous participant but no data entered in past year 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Burton Hospitals NHS Foundation Trust 
Queen’s Hospital, Burton Participant n=14 3 (1, 16) n<6 n=0 21% (3/14) n<6 0% (0/20) 
Calderdale and Huddersfield NHS Foundation Trust 
Huddersfield Royal Infirmary and 
Calderdale Hospital* combined Participant 
n=37  
7 (1, 13) 
n=7  
6 (0, 12) n<6 73% (24/33) n<6 13% (7/54) 
Cambridge University Hospitals NHS Foundation Trust 
Addenbrooke’s Hospital* Participant n=26  11 (5, 16) 
n=7  
7 (5, 14) n<6 46% (11/24) n<6 21% (8/39) 
Central Manchester University Hospitals NHS Foundation Trust 
Manchester Royal Infirmary* Participant n=14  2 (1, 5) 
n=13  
3 (2, 7) n=0 33% (2/6) n<6 52% (11/21) 
Trafford General Hospital Participant n=10  2 (1, 8) n<6 n=0 40% (4/10) n=0 0% (0/10) 
Chelsea and Westminster Hospital NHS Foundation Trust 
Chelsea and Westminster Hospital* Participant n<6 n<6 n<6 n<6 n<6 n<6 
Chesterfield Royal Hospital NHS Foundation Trust 
Chesterfield Royal Hospital* Participant n=55  4 (1, 10) 
n=47  
8 (4, 10) 70% (14/20) 46% (24/52) 14% (3/21) 10% (7/67) 
City Hospitals Sunderland NHS Foundation Trust 
Sunderland Royal Hospital* Participant n=11  4 (1, 10) 
n=7  
9 (7, 11) n<6 n=0 n<6 100% (13/13) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Colchester Hospital University NHS Foundation Trust 
Colchester General Hospital* Participant n=32  10 (3, 17) 
n=16  
14 (10, 16) 50% (3/6) 61% (17/28) 9% (2/22) 11% (4/37) 
Countess of Chester Hospital NHS Foundation Trust 
Countess of Chester Hospital Participant n=25  6 (2, 14) 
n=23  
5 (1, 9) 75% (15/20) 48% (12/25) 9% (2/22) 0% (0/51) 
County Durham and Darlington NHS Foundation Trust 
Darlington Memorial Hospital and 
Bishop Auckland Hospital combined* Participant 
n=27  
3 (1, 13) 
n=28  
9 (6, 12) n<6 68% (17/25) 0% (0/6) 16% (7/43) 
University Hospital of North Durham Participant n=9  5 (2, 9) 
n=9  
7 (6, 10) n<6 44% (4/9) n<6 9% (1/11) 
Croydon Health Services NHS Trust 
Croydon University Hospital Participant n=20  8 (1, 16) 
n=16  
7 (6, 10) 57% (4/7) 90% (18/20) 0% (0/7) 0% (0/23) 
Dartford and Gravesham NHS Trust 
Darent Valley Hospital Previous participant but no data entered in past year 
Derby Hospitals NHS Foundation Trust 
Royal Derby Hospital* Participant n=11  7 (1, 15) 
n=9  
9 (6, 11) n=0 25% (2/8) n<6 47% (8/17) 
Doncaster and Bassetlaw Hospitals NHS Foundation Trust 
Doncaster Royal Infirmary* and 
Bassetlaw District General Hospital 
combined 
Participant n<6 n<6 n<6 n<6 n<6 n<6 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Dorset County Hospital NHS Foundation Trust 
Dorset County Hospital* Participant n=6  4 (1, 10) 
n=6  
5 (4, 11) n<6 n=0 n<6 100% (6/6) 
Ealing Hospital NHS Trust  
Ealing Hospital Non-participant 
East and North Hertfordshire NHS Trust 
Lister Hospital* and Queen Elizabeth II 
Hospital combined Participant 
n=59  
5 (1, 12) 
n=59  
9 (7, 13) 70% (14/20) 59% (30/51) 0% (0/23) 73% (52/71) 
East Cheshire NHS Trust 
Macclesfield District General Hospital  Participant n=25  5 (2, 9) 
n=24  
11 (9, 12) n=0 68% (17/25) n=0 0% (0/27) 
East Kent Hospitals University NHS Foundation Trust 
William Harvey Hospital, Kent and 
Canterbury Hospital and Queen 
Elizabeth The Queen Mother Hospital 
combined  
Participant n=7  10 (1, 20) n<6 n=0 43% (3/7) n=0 0% (0/7) 
East Lancashire Hospitals NHS Trust 
Royal Blackburn Hospital and Burnley 
District General Hospital combined  Participant 
n=73  
4 (1, 11) 
n=48  
7 (3, 11) 42% (10/24) 23% (17/75) 3% (1/40) 50% (46/93) 
East Sussex Healthcare Trust 
Eastbourne District General Hospital 
and Conquest Hospital combined* Participant 
n=8  
1 (0, 13) n<6 n<6 n<6 n<6 40% (4/10) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Epsom and St Helier University Hospitals NHS Trust 
Epsom General Hospital Participant n=7  3 (2, 23) 
n=7  
10 (9, 12) n<6 71% (5/7) n<6 0% (0/10) 
St Helier Hospital  Participant n=6  4 (1, 11) n<6 n=0 83% (5/6) n=0 17% (1/6) 
Frimley Health NHS Foundation Trust 
Frimley Park Hospital* Participant n=32  7 (2, 16) 
n=27  
11 (7, 14) 70% (7/10) 78% (21/27) 13% (2/16) 14% (5/35) 
Heatherwood Hospital Non-participant 
Wexham Park Hospital Participant n<6 n<6 n<6 n<6 n<6 n<6 
Gateshead Health NHS Foundation Trust 
Queen Elizabeth Hospital, Gateshead  Participant but data submitted do not meet audit criteria 
George Eliot Hospital NHS Trust 
George Eliot Hospital  Participant n=37  1 (0, 2) n<6 n=0 43% (16/37) 0% (0/12) 50% (21/42) 
Gloucestershire Hospitals NHS Foundation Trust 
Gloucestershire Royal Hospital and 
Cheltenham General Hospital 
combined*  
Participant n=13  1 (0, 9) 
n=17  
4 (2, 8) 67% (4/6) n=0 14% (1/7) 88% (15/17) 
Great Western Hospitals NHS Foundation Trust  
Great Western Hospital  Participant n=53  4 (1, 11) n<6 n=0 40% (21/53) 100% (1/1) 0% (0/69) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Guy’s and St Thomas’ NHS Foundation Trust 
Guy’s Hospital and St Thomas’ Hospital 
combined* Participant 
n=14  
1 (1, 6) 
n=17  
5 (4, 9) n<6 n=0 n<6 94% (16/17) 
Hampshire Hospitals NHS Foundation Trust 
Basingstoke and North Hampshire 
Hospitals*  Participant 
n=10  
3 (1, 14) 
n=10  
9 (5, 12) n<6 n=0 n<6 100% (10/10) 
Royal Hampshire County Hospital* Participant n=12  2 (0, 19) 
n=15  
7 (4, 15) n<6 n=0 n<6 93% (14/15) 
Harrogate and District NHS Foundation Trust 
Harrogate District Hospital  
Previous 
participant but 
no data entered 
in past year 
n=8  
4 (1, 7) n<6 n=0 50% (4/8) n=0 0% (0/10) 
Heart of England NHS Foundation Trust 
Birmingham Heartlands Hospital and 
Solihull Hospital combined  Participant n<6 n<6 n<6 n<6 n<6 n<6 
Good Hope Hospital Participant n=6  5 (2, 10) n<6 n=0 67% (4/6) n<6 0% (0/7) 
Hinchingbrooke Health Care NHS Trust 
Hinchingbrooke Hospital Participant but data submitted do not meet audit criteria 
Homerton University Hospital NHS Foundation Trust  
Homerton University Hospital  Participant n=49  4 (1, 12) 
n=44  
9 (7, 10) 32% (6/19) 84% (41/49) 5% (1/21) 6% (4/63) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Hull and East Yorkshire Hospitals NHS Trust 
Hull Royal Infirmary* and Castle Hill 
Hospital combined  Participant 
n=62  
2 (0, 8) 
n=49  
5 (2, 7) 79% (19/24) 63% (17/27) 5% (2/40) 79% (53/67) 
Imperial College Healthcare NHS Trust 
Charing Cross Hospital, Hammersmith 
Hospital and St Mary’s Hospital 
combined  
Previous participant but no data entered in past year 
James Paget University Hospitals NHS Foundation Trust 
James Paget Hospital*  Participant n=6  0 (0, 3) 
n=6  
7 (1, 10) n<6 n<6 n<6 83% (5/6) 
Kettering General Hospital NHS Foundation Trust 
Kettering General Hospital  Previous participant but no data entered in past year 
King’s College Hospital NHS Foundation Trust  
King’s College Hospital Participant n<6 n<6 n<6 n<6 n<6 n<6 
Princess Royal University Hospital  Participant n=8  4 (1, 12) n<6 n=0 63% (5/8) n=0 0% (0/16) 
Kingston Hospital NHS Trust 
Kingston Hospital  Participant n=15  1 (1, 6) n<6 n=0 73% (11/15) n=0 0% (0/19) 
Lancashire Teaching Hospitals NHS Foundation Trust 
Royal Preston Hospital and Chorley and 
South Ribble Hospital combined  Participant but data submitted do not meet audit criteria 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Lewisham and Greenwich NHS Trust 
Lewisham Hospital  Participant n<6 n<6 n=0 n<6 n<6 0% (0/7) 
Queen Elizabeth Hospital, Woolwich Participant but data submitted do not meet audit criteria 
London North West Healthcare NHS Trust 
Central Middlesex Hospital Participant but data submitted do not meet audit criteria 
Northwick Park and St Mark's Hospitals 
Combined*  Participant 
n=14  
20 (8, 29) 
n=16  
5 (2, 10) 67% (8/12) n=0 0% (0/12) 100% (16/16) 
Luton and Dunstable Hospital NHS Foundation Trust 
Luton and Dunstable Hospital*  Participant n<6 n<6 n=0 n=0 n<6 0% (0/6) 
Maidstone and Tunbridge Wells NHS Trust 
Maidstone Hospital*  Participant n<6 n<6 n<6 n<6 n<6 n<6 
Tunbridge Wells Hospital Participant n=19  8 (3, 16) 
n=11  
9 (0, 9) n=0 53% (10/19) n<6 10% (2/20) 
Medway NHS Foundation Trust 
Medway Maritime Hospital  Participant n=18  4 (2, 13) n<6 n=0 72% (13/18) n<6 0% (0/20) 
Mid Cheshire Hospitals NHS Foundation Trust 
Leighton Hospital*  Participant n<6 n<6 n<6 n<6 n<6 n<6 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Mid Essex Hospitals NHS Trust 
Broomfield Hospital  Participant n=25  6 (2, 12) 
n=23  
10 (9, 12) n=0 52% (13/25) n=0 0% (0/25) 
Milton Keynes Hospital NHS Foundation Trust 
Milton Keynes Hospital*  Participant n<6 n=8  7 (4, 11) n<6 n=0 n<6 100% (8/8) 
NHS Isle of Wight 
St Mary’s Hospital  Previous participant but no data entered in past year 
Norfolk and Norwich University Hospitals NHS Foundation Trust 
Norfolk and Norwich University 
Hospital*  Participant 
n=12  
4 (2, 9) 
n=12  
3 (1, 6) n<6 n=0 n<6 100% (12/12) 
North Bristol NHS Trust 
Southmead hospital  Participant n=13  3 (1, 10) n<6 n=0 62% (8/13) n<6 7% (1/14) 
North Cumbria University Hospitals NHS Trust 
Cumberland Infirmary*  Participant n=13  4 (2, 9) n<6 n=0 46% (5/11) n<6 14% (2/14) 
West Cumberland Hospital* Participant n=9  2 (1, 8) n<6 n=0 100% (7/7) n<6 13% (2/15) 
North Middlesex University Hospital NHS Trust 
North Middlesex University Hospital  Previous participant but no data entered in past year 
  
 
 ©
 Healthcare Q
uality Im
provem
ent Partnership 2015 
 
N
ational clinical audit of biological therapies. Adult report. Septem
ber 2015. U
K IBD audit 
 
 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
North Tees and Hartlepool NHS Foundation Trust 
University Hospital of Hartlepool  Participant n<6 n<6 n<6 n<6 n<6 n<6 
University Hospital of North Tees Participant n=31  4 (1, 13) n<6 n=0 55% (17/31) 11% (2/19) 13% (5/40) 
Northampton General Hospital NHS Trust 
Northampton General Hospital  Participant n=36  6 (1, 13) n<6 n<6 44% (16/36) 0% (0/9) 0% (0/53) 
Northern Devon Healthcare NHS Trust 
North Devon District Hospital  
Previous 
participant but 
no data entered 
in past year 
n<6 n<6 n<6 n<6 n<6 n<6 
Northern Lincolnshire and Goole Hospitals NHS Foundation Trust 
Diana, Princess of Wales Hospital Participant n=26  4 (1, 9) n<6 n=0 62% (16/26) n<6 0% (0/45) 
Scunthorpe General Hospital  
Previous 
participant but 
no data entered 
in past year 
n=9  
4 (2, 10) n<6 n=0 67% (6/9) n<6 0% (0/10) 
Northumbria Healthcare NHS Foundation Trust 
Northumbria Healthcare NHS 
Foundation Trust (Wansbeck, North 
Tyneside and Hexham General 
Hospitals combined)  
Participant n=28  5 (1, 12) 
n=27  
11 (8, 14) 43% (3/7) 61% (17/28) 0% (0/8) 38% (12/32) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Nottingham University Hospital NHS Trust 
Queen’s Medical Centre* and 
Nottingham City Hospital combined  Participant 
n=7  
3 (1, 17) 
n=10  
7 (3, 9) n<6 n=0 33% (2/6) 100% (10/10) 
Oxford University Hospitals NHS Trust 
The John Radcliffe Hospital and Horton 
General Hospital combined  Participant 
n=36  
3 (1, 8) n<6 n=0 67% (24/36) 13% (1/8) 0% (0/41) 
Peterborough and Stamford Hospitals NHS Foundation Trust 
Peterborough City Hospital  Participant n=26  8 (2, 22) n<6 n<6 65% (17/26) 0% (0/8) 0% (0/31) 
Plymouth Hospitals NHS Trust 
Derriford Hospital* Participant n=9  0 (0, 7) 
n=10  
4 (2, 8) n=0 n=0 0% (0/6) 93% (13/14) 
Poole Hospital NHS Foundation Trust  
Poole General Hospital*  Participant n=8  5 (0, 10) 
n=8  
6 (3, 8) n=0 n=0 n<6 94% (15/16) 
Portsmouth Hospitals NHS Trust 
Queen Alexandra Hospital*  Participant n=51  6 (1, 14) 
n=10  
4 (4, 7) 57% (4/7) 64% (27/42) 0% (0/7) 12% (8/65) 
Princess Alexandra Hospital NHS Trust 
Princess Alexandra Hospital, Harlow*  Participant n=14  4 (0, 13) 
n=17  
11 (6, 15) n<6 n=0 0% (0/6) 100% (17/17) 
Royal Berkshire NHS Foundation Trust 
Royal Berkshire Hospital*  Participant n=9  1 (1, 13) 
n=10  
5 (3, 14) n<6 n=0 n<6 100% (10/10) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Royal Bolton Hospital NHS Foundation Trust 
Royal Bolton Hospital  Participant n=65  6 (2, 12) 
n=45  
5 (3, 9) 38% (3/8) 81% (54/67) 6% (1/16) 10% (9/91) 
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust 
Royal Bournemouth Hospital* Participant n=97  5 (1, 15) 
n=95  
7 (5, 11) 64% (28/44) 60% (55/91) 6% (3/48) 8% (10/121) 
Royal Cornwall Hospitals NHS Trust 
Royal Cornwall Hospital* Participant n=27  7 (2, 16) 
n=10  
6 (2, 6) n<6 57% (13/23) 0% (0/11) 30% (11/37) 
Royal Devon and Exeter NHS Foundation Trust 
Royal Devon and Exeter Hospital* Participant n=47  1 (0, 4) 
n=48  
6 (3, 10) 81% (21/26) n=0 4% (1/27) 86% (42/49) 
Royal Free London NHS Foundation Trust 
Barnet General Hospital 
Previous 
participant but 
no data entered 
in past year 
n=6  
4 (1, 15) 
n=6  
22 (14, 25) n=0 83% (5/6) n=0 0% (0/8) 
Royal Free Hospital* Participant n=8   6 (2, 14) n<6 n=0 50% (3/6) n<6 42% (5/12) 
Royal Liverpool and Broadgreen University Hospitals NHS Trust 
Royal Liverpool University Hospital  Participant n=28  2 (1, 7) 
n=27  
7 (0, 10) n<6 64% (18/28) 0% (0/6) 0% (0/33) 
Royal Surrey County Hospital NHS Foundation Trust 
Royal Surrey County Hospital  Participant n=7  10 (2, 27) 
n=6  
14 (12, 14) n=0 71% (5/7) n=0 0% (0/9) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Royal United Hospital Bath NHS Trust 
Royal United Hospital  Non-participant 
Salford Royal NHS Foundation Trust 
Salford Royal Hospital* Participant n=108  7 (2, 15) 
n=85  
9 (8, 11) 12% (6/49) 36% (38/106) 13% (7/56) 2% (2/114) 
Salisbury NHS Foundation Trust 
Salisbury District General Hospital  Participant n=19  2 (1, 6) n<6 n=0 37% (7/19) n<6 0% (0/32) 
Sandwell and West Birmingham Hospitals NHS Trust 
Birmingham City Hospital and Sandwell 
Hospital combined* Participant 
n=20  
6 (1, 12) 
n=11  
8 (5, 9) n<6 75% (6/8) n<6 44% (10/23) 
Sheffield Teaching Hospitals NHS Foundation Trust 
Royal Hallamshire Hospital and 
Northern General Hospital combined  Participant 
n=145  
6 (2, 13) 
n=99  
7 (4, 10) 64% (16/25) 44% (64/146) 0% (0/42) 65% (125/192) 
Sherwood Forest Hospitals NHS Foundation Trust 
King’s Mill Hospital and Newark 
Hospital combined* Participant 
n=30  
2 (1, 9) 
n=20  
4 (2, 7) 67% (4/6) 33% (5/15) 10% (1/10) 55% (18/33) 
South Devon Healthcare NHS Foundation Trust 
Torbay Hospital* Participant n=24  5 (1, 18) 
n=24  
8 (4, 12) 64% (7/11) n=0 23% (3/13) 100% (24/24) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
South Tees Hospitals NHS Foundation Trust 
Friarage Hospital Non-participant 
James Cook University Hospital* Participant n=15  2 (0, 15) 
n=12  
4 (2, 11) 88% (7/8) n<6 0% (0/8) 56% (10/18) 
South Tyneside NHS Foundation Trust 
South Tyneside District Hospital* Participant n=23  5 (2, 14) 
n=24  
5 (3, 7) 86% (12/14) 58% (11/19) 11% (2/18) 30% (10/33) 
South Warwickshire NHS Foundation Trust 
Warwick Hospital  Participant n=75  3 (1, 10) n<6 n=0 32% (24/75) n=0 0% (0/89) 
Southend University Hospital NHS Foundation Trust 
Southend University Hospital  
Previous 
participant but 
no data entered 
in past year 
n<6 n<6 n=0 n<6 n<6 0% (0/11) 
Southport and Ormskirk Hospital NHS Trust 
Southport District General Hospital  Previous participant but no data entered in past year 
St George’s Healthcare NHS Trust 
St George’s Hospital* Participant n=39  8 (2, 11) 
n=42  
10 (9, 12) 67% (10/15) 74% (26/35) 16% (3/19) 31% (15/48) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
St Helens and Knowsley Hospitals NHS Trust 
Whiston Hospital  Participant but data submitted do not meet audit criteria 
Stockport NHS Foundation Trust 
Stepping Hill Hospital* Participant n<6 n<6 n<6 n<6 n<6 n<6 
Surrey and Sussex Healthcare NHS Trust 
East Surrey Hospital  Previous participant but no data entered in past year 
Tameside Hospital NHS Foundation Trust 
Tameside General Hospital*  Participant n<6 n<6 n<6 n<6 n<6 43% (3/7) 
Taunton and Somerset NHS Foundation Trust 
Musgrove Park Hospital* Participant n=14  4 (1, 17) 
n=11  
0 (0, 5) n<6 55% (6/11) n<6 95% (19/20) 
The Dudley Group NHS Foundation Trust 
Russells Hall Hospital* Participant n=43  4 (1, 12) 
n=39  
8 (5, 10) n<6 62% (26/42) 10% (1/10) 49% (32/65) 
The Hillingdon Hospitals NHS Foundation Trust 
Hillingdon Hospital  Non-participant 
The Ipswich Hospital NHS Trust 
The Ipswich Hospital  Previous participant but no data entered in past year 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
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Bradshaw Index, 
Median (IQR) 
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disease 
patients – 
remission 
achieved 
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immunosuppression 
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Crohn’s 
disease 
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up 
All patients –
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start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
The Leeds Teaching Hospitals NHS Trust 
Leeds General Infirmary* Participant n<6 n<6 n=0 n<6 n<6 n<6 
St James’s University Hospital Leeds*  Participant n=14  5 (1, 10) 
n=15  
5 (2, 7) 67% (4/6) n=0 13% (1/8) 94% (16/17) 
The Mid Yorkshire Hospitals NHS Trust 
Dewsbury and District Hospital  Non-participant 
Pinderfields General Hospital and 
Pontefract Hospitals combined* Participant 
n=12  
2 (0, 5) 
n=16  
2 (0, 9) n<6 n=0 0% (0/6) 82% (14/17) 
The Newcastle upon Tyne Hospitals NHS Foundation Trust 
Freeman Hospital Participant n=40  9 (2, 20) 
n=10  
11 (6, 17) n<6 43% (17/40) 5% (1/22) 0% (0/43) 
Royal Victoria Infirmary, Newcastle* Participant n=23  3 (1, 10) 
n=24  
6 (3, 10) 83% (15/18) n=0 5% (1/19) 100% (24/24) 
The Pennine Acute Hospitals NHS Trust 
The Royal Oldham Hospital, Fairfield 
General Hospital, North Manchester 
General Hospital and Rochdale 
Infirmary combined* 
Participant n=88  5 (1, 11) 
n=11  
5 (4, 10) n<6 55% (43/78) n<6 9% (10/107) 
The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust 
The Queen Elizabeth Hospital  Previous participant but no data entered in past year 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
The Rotherham NHS Foundation Trust 
Rotherham Hospital  Participant n=13  5 (2, 12) 
n=6  
11 (5, 18) n<6 54% (7/13) n<6 0% (0/17) 
The Royal Wolverhampton Hospitals NHS Trust 
Cannock Chase Hospital Participant n<6 n<6 n=0 n<6 n<6 n<6 
New Cross Hospital* Participant n=60  5 (2, 12) 
n=46  
8 (5, 9) 47% (9/19) 46% (25/54) 0% (0/21) 26% (22/84) 
The Shrewsbury and Telford Hospital NHS Trust 
Royal Shrewsbury Hospital* and 
Princess Royal Hospital combined  Participant 
n=13  
6 (1, 11) 
n=15  
5 (4, 10) 71% (5/7) n<6 0% (0/8) 88% (14/16) 
United Lincolnshire Hospitals NHS Trust 
Grantham and District Hospital* Participant n=6  1 (1, 6) 
n=6  
8 (1, 8) n<6 n<6 n<6 14% (1/7) 
Lincoln County Hospital* Participant n=18  2 (1, 5) 
n=6  
6 (5, 10) n<6 53% (8/15) n<6 13% (3/23) 
Pilgrim Hospital  Participant n=17  5 (1, 17) n<6 n=0 53% (9/17) 17% (1/6) 0% (0/19) 
University College London Hospitals NHS Foundation Trust 
University College Hospital* Participant n=70  4 (1, 8) 
n=57  
7 (3, 9) 73% (16/22) 75% (51/68) 10% (3/30) 4% (3/80) 
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Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
University Hospitals of North Midlands NHS Trust 
County Hospital Participant but data submitted do not meet audit criteria 
The Royal Stoke University Hospital* Participant n<6 n<6 n<6 n<6 n<6 n<6 
University Hospital of South Manchester NHS Foundation Trust 
Wythenshawe Hospital* Participant n=30  4 (1, 10) 
n=29  
10 (6, 14) 83% (5/6) 59% (10/17) 0% (0/6) 34% (13/38) 
University Hospital Southampton NHS Foundation Trust 
Southampton General Hospital* Participant n=48  3 (1, 10) 
n=47  
7 (4, 13) 52% (11/21) 46% (5/11) 10% (3/30) 77% (46/60) 
University Hospitals Birmingham NHS Foundation Trust 
Queen Elizabeth Hospital, Birmingham  Participant n=134  8 (3, 15) 
n=14  
8 (3, 11) n=0 44% (60/135) 11% (11/102) 5% (9/170) 
New Queen Elizabeth Hospital 
Birmingham* Participant 
n=7  
3 (0, 15) 
n=9  
4 (0, 10) n<6 n=0 n<6 100% (10/10) 
University Hospitals Coventry and Warwickshire NHS Trust 
University Hospital, Coventry* Participant n=18  4 (1, 19) 
n=18  
5 (3, 9) n<6 n=0 n<6 100% (18/18) 
University Hospitals of Bristol NHS Foundation Trust 
Bristol Royal Infirmary*  Participant n=10  3 (1, 5) 
n=6  
6 (2, 9) n<6 44% (4/9) n<6 15% (2/13) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
University Hospitals of Leicester NHS Trust 
Leicester Royal Infirmary  
Previous 
participant but 
no data entered 
in past year 
n=8  
2 (1, 3) n<6 n=0 38% (3/8) n=0 0% (0/8) 
Leicester General Hospital* Participant n<6 n<6 n<6 n<6 n<6 n<6 
University Hospitals of Morecombe Bay NHS Foundation Trust 
Furness General and Royal Lancaster 
Infirmary and Westmorland General 
Hospitals combined 
Participant n=22  9 (2, 20) n<6 n=0 59% (13/22) n<6 0% (0/27) 
Walsall Healthcare NHS Trust 
Walsall Manor Hospital  
Previous 
participant but 
no data entered 
in past year 
n=21  
2 (1, 8) 
n=19  
13 (10, 16) n<6 52% (11/21) n<6 65% (20/31) 
Warrington and Halton Hospitals NHS Foundation Trust 
Warrington District General Hospital* Participant n=18  5 (2, 11) 
n=17  
7 (5, 13) n<6 n<6 n<6 57% (13/23) 
West Hertfordshire Hospitals NHS Trust 
Watford General Hospital* and Hemel 
Hempstead General Hospital combined  Participant 
n=66  
3 (1, 10) 
n=48  
10 (8, 13) 65% (11/17) 51% (32/63) 5% (2/40) 4% (3/70) 
West Middlesex University Hospital NHS Trust 
West Middlesex University Hospital* Participant n=17  5 (2, 13) 
n=17  
10 (8, 12) n=0 56% (9/16) n<6 5% (1/22) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
West Suffolk Hospitals NHS Foundation Trust 
West Suffolk Hospital  Participant n=15  4 (1, 12) 
n=14  
14 (11, 21) 29% (2/7) 27% (4/15) 10% (1/10) 0% (0/17) 
Western Sussex Hospitals NHS Trust 
St Richard’s Hospital Participant n=19  6 (1, 15) 
n=11  
8 (2, 9) n=0 68% (13/19) n=0 0% (0/25) 
Worthing Hospital*  Participant n=7  0 (0, 8) n<6 n<6 n<6 n<6 57% (4/7) 
Weston Area Health Trust 
Weston General Hospital*  Participant n=19  11 (1, 20) 
n=20  
9 (5, 12) n<6 21% (3/14) 11% (1/9) 69% (18/26) 
Whittington Health NHS Trust 
Whittington Hospital  Participant but data submitted do not meet audit criteria 
Wirral University Teaching Hospital NHS Foundation Trust 
Arrowe Park Hospital  Participant n=31  5 (2, 19) 
n=16  
7 (6, 9) n<6 36% (11/31) 0% (0/7) 0% (0/31) 
Worcestershire Acute Hospitals NHS Trust 
Alexandra Hospital Not eligible 
Worcestershire Royal Hospital  
Previous 
participant but 
no data entered 
in past year 
n=12  
10 (2, 16) n<6 n=0 67% (8/12) n=0 0% (0/17) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Wrightington, Wigan and Leigh NHS Foundation Trust  
Royal Albert Edward Infirmary* Participant n=7  6 (2, 33) 
n=7  
7 (1, 11) n<6 n=0 n<6 100% (7/7) 
Wye Valley NHS Trust 
County Hospital, Hereford Participant n=19  2 (1, 9) 
n=18  
9 (7, 14) 38% (3/8) 42% (8/19) 0% (0/8) 0% (0/20) 
Yeovil District Hospital NHS Foundation Trust 
Yeovil District Hospital* Participant n=37  6 (1, 16) 
n=23  
6 (4, 7) 60% (6/10) 36% (11/31) 33% (7/21) 92% (54/59) 
York Teaching Hospital NHS Foundation Trust 
Scarborough General Hospital Previous participant but no data entered in past year 
York Hospital Participant n=15  4 (1, 12) n<6 n=0 60% (9/15) n=0 0% (0/18) 
Northern Ireland (n=12) 
Belfast Health and Social Care Trust 
Belfast City Hospital Participant n=30  3 (1, 10) 
n=7  
6 (5, 8) n=0 67% (20/30) n<6 23% (8/35) 
Mater Hospital Previous participant but no data entered in past year 
Royal Victoria Hospital Participant n=15  5 (0, 14) n<6 n=0 80% (12/15) n=0 0% (0/16) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Northern Health and Social Care Trust 
Antrim Area Hospital Previous participant but no data entered in past year 
Causeway Hospital Participant n=8  5 (1, 8) n<6 n=0 25% (2/8) n=0 0% (0/13) 
South Eastern Health and Social Care Trust 
Downe Hospital Non-participant 
Lagan Valley Hospital  Participant n=6  3 (1, 5) 
n=6  
11 (7, 16) n=0 50% (3/6) n<6 0% (0/6) 
Ulster Hospital Participant n<6 n<6 n<6 n<6 n<6 n<6 
Southern Health and Social Care Trust 
Craigavon Area Hospital 
Previous 
participant but 
no data entered 
in past year 
n=8  
7 (1, 14) n<6 n=0 88% (7/8) n=0 9% (1/11) 
Daisy Hill Hospital Participant n=7  3 (0, 10) n<6 n=0 43% (3/7) n<6 44% (4/9) 
Western Health and Social Care Trust 
Altnagelvin Area Hospital 
Previous 
participant but 
no data entered 
in past year 
n=8  
13 (3, 22) 
n=8  
10 (4, 13) n=0 50% (4/8) n=0 0% (0/9) 
South West Acute Hospital Previous participant but no data entered in past year 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Scotland (n=21) 
NHS Ayrshire and Arran 
University Hospital Ayr Non-participant 
University Hospital Crosshouse Previous participant but no data entered in past year 
NHS Borders 
Borders General Hospital Previous participant but no data entered in past year 
NHS Dumfries and Galloway 
Dumfries and Galloway Royal Infirmary Participant n<6 n<6 n<6 n<6 n<6 n<6 
NHS Fife 
Queen Margaret Hospital Non-participant 
Victoria Hospital* Participant n<6 n<6 n<6 n<6 n<6 n<6 
NHS Forth Valley 
Forth Valley Royal Hospital* Participant n=46  4 (1, 9) 
n=18  
4 (0, 8) 86% (6/7) 65% (22/34) 5% (1/22) 96% (65/68) 
NHS Grampian 
Aberdeen Royal Infirmary Non-participant 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
NHS Greater Glasgow and Clyde 
Glasgow Royal Infirmary* Participant n=11  5 (1, 7) 
n=11  
5 (3, 9) n<6 n=0 n<6 91% (10/11) 
Inverclyde Royal Hospital Previous participant but no data entered in past year 
Royal Alexandra Hospital Previous participant but no data entered in past year 
Southern General Hospital Non-participant 
Victoria Infirmary Non-participant 
Western Infirmary Non-participant 
NHS Highland 
Raigmore Hospital Non-participant 
NHS Lanarkshire 
Hairmyres Hospital Participant n=9  8 (2, 14) 
n=8  
8 (4, 9) n<6 44% (4/9) n<6 0% (0/9) 
Monklands Hospital Participant n=14  8 (1, 17) 
n=7  
9 (5, 10) n<6 57% (8/14) n<6 43% (6/14) 
Wishaw General Hospital Previous participant but no data entered past year 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
NHS Lothian 
St John’s Hospital at Howden Non-participant 
Western General Hospital and Royal 
Infirmary of Edinburgh combined* Participant 
n=17  
4 (1, 9) 
n=14  
7 (4, 10) n<6 n<6 0% (0/6) 62% (13/21) 
NHS Tayside 
Ninewells Hospital* Participant n=15  5 (2, 18) 
n=7  
6 (0, 8) n=0 47% (7/15) n<6 23% (6/26) 
Wales (n=16) 
Abertawe Bro Morgannwg University Health Board 
Morriston Hospital Not eligible 
Princess of Wales Hospital Non-participant 
Aneurin Bevan University Health Board 
Nevill Hall Hospital Participant n=41  4 (1, 8) 
n=24  
6 (2, 10) n<6 49% (20/41) 0% (0/9) 46% (23/50) 
Royal Gwent Hospital Participant n=18  4 (1, 11) 
n=16  
8 (4, 10) n<6 44% (8/18) n<6 75% (18/24) 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Betsi Cadwaladr University Health Board 
Glan Clwyd Hospital Non-participant 
Llandudno General Hospital Previous participant but no data entered in past year 
Wrexham Maelor Hospital Participant n=38  3 (1, 13) 
n=19  
10 (8, 12) n<6 45% (17/38) 7% (2/29) 19% (8/42) 
Ysbyty Gwynedd Participant but data submitted do not meet audit criteria 
Cardiff and Vale University Health Board 
University Hospital Llandough Participant n=10  8 (3, 16) 
n=10  
6 (3, 8) n=0 64% (7/11) n=0 39% (5/13) 
University Hospital of Wales 
Previous 
participant but 
no data entered 
in past year 
n=25  
3 (1, 12) 
n=22  
5 (3, 9) 89% (8/9) 76% (19/25) 0% (0/9) 78% (21/27) 
Cwm Taf University Health Board 
Prince Charles Hospital Non-participant 
Royal Glamorgan Hospital Non-participant 
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 Participation status 
Crohn’s disease 
patients – time 
from diagnosis to 
initial treatment, 
years, Median 
(IQR) 
Initial treatment 
Harvey 
Bradshaw Index, 
Median (IQR) 
Crohn’s 
disease 
patients – 
remission 
achieved 
Crohn’s disease 
patients – On 
concomitant 
immunosuppression 
at start of 
treatment 
Crohn’s 
disease 
patients with 
adverse event 
recorded at 3 
month follow-
up 
All patients –
PROMs 
completed at 
start of 
treatment 
Results  (n=3739) 4 (1, 12) 
n=2282 
8 (4, 10) 68% (502/741) 53% (1644/3080) 
n=1343 
8% (108) 
30%  
(1416/4718) 
Hywel Dda University Health Board 
Bronglais General Hospital Participant n<6 n<6 n<6 n<6 n<6 n<6 
Glangwili General Hospital Previous participant but no data entered in past year 
Prince Philip Hospital Non-participant 
Withybush General Hospital Participant n=17  5 (1, 13) 
n=16  
8 (6, 10) n<6 77% (13/17) n<6 30% (6/20) 
CD = Crohn’s disease; IQR = interquartile range; PROMs = patient-reported outcome measures. 
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Appendices 
 
Appendix 1: Acronyms used in this report 
 
Anti-TNFα Anti-tumour necrosis factor alpha 
AoMRC Academy of Medical Royal Colleges 
CD Crohn’s disease 
CEEU Clinical Effectiveness and Evaluation Unit 
CUCQ-12 Crohn’s and ulcerative colitis questionnaire 
HBI Harvey–Bradshaw index 
HQIP Healthcare Quality Improvement Partnership 
IBD Inflammatory bowel disease 
IBDU Inflammatory bowel disease type unclassified 
IQR Interquartile range 
NCAPOP National Clinical Audit and Patient Outcomes Programme 
NICE National Institute for Health and Care Excellence 
PANTs Personalised Anti-TNF Therapy in Crohn’s disease study 
PCDAI Paediatric Crohn’s Disease Activity Index 
PROMs Patient-reported outcome measures 
RCN Royal College of Nursing 
RCP Royal College of Physicians 
SCCAI Simple Clinical Colitis Activity Index 
UC  Ulcerative colitis 
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Appendix 2: Biological therapy audit governance 
 
Audit governance 
The fourth round of the UK IBD audit is guided by the multidisciplinary IBD programme steering group, 
which is a collaborative partnership between gastroenterologists (the British Society of 
Gastroenterology), colorectal surgeons (the Association of Coloproctology of Great Britain and Ireland), 
patients (Crohn’s and Colitis UK), physicians (the RCP), nurses (the Royal College of Nursing (RCN), 
pharmacists (the Royal Pharmaceutical Society), dietitians (the British Dietetic Association) and 
paediatric gastroenterologists (the British Society of Paediatric Gastroenterology, Hepatology and 
Nutrition).  
 
The audit is commissioned by HQIP as part of the National Clinical Audit and Patient Outcomes 
Programme (NCAPOP). The audit is managed by the Clinical Effectiveness and Evaluation Unit of the 
RCP. Each hospital identified an overall clinical lead who was responsible for data collection and entry 
for their IBD service. Data were collected by hospitals using a standardised method.  
 
Any enquiries in relation to the work of the UK IBD audit can be directed to ibd.audit@rcplondon.ac.uk. 
 
IBD programme steering group members 
The names of members of the biological therapy audit subgroup are shown in bold. This is the group of 
people tasked with leading this particular element of the UK IBD audit and who contributed 
considerably to the development of this element of work. 
 
Association of Coloproctology of Great Britain and Ireland  
Mr Omar Faiz, consultant colorectal surgeon, St Mark’s Hospital, Harrow 
Mr Graeme Wilson, consultant colorectal surgeon, Western General Hospital, Edinburgh 
British Dietetic Association  
Ms Katie Keetarut, senior IBD dietitian, University College Hospital, London 
British Society of Gastroenterology 
Dr Ian Arnott, clinical director of the IBD programme, chair of the UK IBD audit steering group; 
consultant gastroenterologist, Western General Hospital, Edinburgh 
Dr Stuart Bloom, consultant gastroenterologist, University College Hospital, London 
Dr Keith Bodger, consultant physician and gastroenterologist, University Hospital Aintree, Liverpool 
Dr Fraser Cummings, consultant gastroenterologist, University Hospital Southampton 
Professor Chris Probert, consultant gastroenterologist, Royal Liverpool University Hospital 
Dr Ian Shaw, IBD programme associate director; consultant gastroenterologist, Gloucestershire 
Royal Hospital 
Dr Graham Turner, consultant gastroenterologist, Royal Victoria Hospital, Belfast  
Professor John Williams, consultant gastroenterologist, Abertawe Bro Morgannwg University 
Health Board; director, Health Informatics Unit, RCP 
British Society of Paediatric Gastroenterology, Hepatology and Nutrition 
Dr Charles Charlton, consultant paediatric gastroenterologist, Queens Medical Centre, Nottingham  
Dr Sally Mitton, consultant paediatric gastroenterologist, St George’s Hospital, London 
Dr Richard Russell, consultant paediatric gastroenterologist, Royal Hospital for Sick Children 
(Yorkhill), Glasgow 
Crohn’s and Colitis UK (NACC) 
Mr David Barker, chief executive 
Mr Peter Canham, patient involvement adviser 
Ms Jackie Glatter, health service development adviser 
Revd Ian Johnston, patient representative 
Primary Care Society for Gastroenterology 
Dr Jamie Dalrymple, GP partner, Drayton and St Faiths medical practice 
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Royal College of Nursing 
Ms Kay Crook, paediatric gastroenterology clinical nurse specialist, St Mark’s Hospital, Harrow 
Ms Diane Hall, clinical nurse specialist, Heartlands Hospital, Birmingham 
Dr Karen Kemp, IBD clinical nurse specialist, Manchester Royal Infirmary 
Royal College of Physicians 
Ms Rhona Buckingham, operations director, CEEU 
Ms Kajal Mortier, project manager, UK IBD programme 
Ms Susan Murray, programme manager, UK IBD programme  
Ms Aimee Protheroe, programme development manager, UK IBD disease programme 
Dr Kevin Stewart, clinical director, CEEU 
Royal Pharmaceutical Society of Great Britain 
Ms Anja St Clair-Jones, lead pharmacist – surgery and digestive diseases, Royal Sussex County 
Hospital, Brighton 
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Appendix 3: Consort diagram – follow-up treatment  
 
Fig 3 Consort diagram for follow-up treatment of adult patients. CD = Crohn’s disease; IBDU = 
inflammatory bowel disease type unclassified; PANTs = Personalised Anti-TNF Therapy in Crohn’s 
disease study; UC = ulcerative colitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=470 
Patients with data  
at 12-month follow-up 
n=3898  
Patients with 
complete audit data  
(demographic, 
disease and initial 
treatment data) n=9140  
Follow-up records with 
matching initial audit data 
n=18,892  
Follow-up records 
n=18,693  
Follow-up records 
n=197 
Excluded because  
no date of follow-up 
 
n=2 
Excluded because of  
blank record or one treatment 
contained within timescale  
of another 
n=1218  
Patients with data  
at 3-month follow-up 
n=586  
Patients with data  
at 12-month follow-up 
n=116 
Patients with  
12-month follow-up 
from PANTs  
n=1561 
Patients with data  
at 3-month follow-up 
n=343  
Patients with 
 3-month follow-up 
from PANTs  
Adalimumab:  
n=186 
181 CD 
3 UC 
2 IBDU 
 
Infliximab:  
n=400 
 339 CD 
49 UC 
12 IBDU 
Adalimumab:  
n=556 
525 CD  
19 UC 
12 IBDU 
Infliximab:  
n=1005 
 818 CD  
157 UC  
30 IBDU 
n=18,695  
Follow-up records 
96 
© Healthcare Quality Improvement Partnership 2015 
National clinical audit of biological therapies. Adult report. September 2015. UK IBD audit 
References 
 
1 IBD Standards Group, 2013. Standards for the healthcare of people who have inflammatory bowel 
disease, IBD standards, 2013 update. www.ibdstandards.org.uk [Accessed 17 July 2015]. 
2 National Institute for Health and Care Excellence, 2011. Technology appraisal 187: Infliximab 
(review) and adalimumab for the treatment of Crohn’s disease. www.nice.org.uk/guidance/TA187 
[Accessed 17 July 2015]. 
3 National Institute for Health and Care Excellence, 2011. Technology appraisal 329: Infliximab, 
adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the 
failure of conventional therapy (including a review of TA140 and TA262). 
www.nice.org.uk/guidance/TA329 [Accessed 17 July 2015]. 
4 National Institute for Health and Care Excellence, 2015. Quality standard 81: Inflammatory bowel 
disease. www.nice.org.uk/guidance/QS81 [Accessed 17 July 2015]. 
5 Personalised Anti-TNF Therapy in Crohn’s disease study (PANTs). www.pantsdb.co.uk [Accessed 
17 July 2015]. 
6 Royal College of Physicians, 2014. National clinical audit of biological therapies. UK IBD audit. Adult 
report.  www.rcplondon.ac.uk/sites/default/files/national_clinical_audit_report_of_biological 
_therapies_-_adult_report_sep_2014_web.pdf [Accessed 1 September 2015]. 
7 Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory 
bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53 
8 Royal College of Physicians, 2014. National audit of inflammatory bowel disease (IBD) service 
provision. Adult report. www.rcplondon.ac.uk/sites/default/files/national_ibd_organisational 
_audit_adult_report_final_web.pdf [Accessed 1 September 2015]. 
9 EuroQol. EQ-5D™ is a standardised instrument for use as a measure of health outcome. 
www.euroqol.org [Accessed 17 July 2015]. 
10 Alrubaiy L, Cheung WY, Dodds F, Hutchings HA, Russell IT et al. Development of a short 
questionnaire to assess the quality of life in Crohn’s disease and ulcerative colitis. J Crohns Colitis 
2015;9:66–76. 
11 Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory 
bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54. 
12 National Institute for Health and Care Excellence, 2008. Technology appraisal 163: Infliximab for 
acute exacerbations of ulcerative colitis. www.nice.org.uk/guidance/TA163 [Accessed 17 July 
2015]. 
13 Royal College of Physicians, 2011. UK inflammatory bowel disease audit biologics audit system and 
hosted server security details. 
www.rcplondon.ac.uk/sites/default/files/biologics_audit_system_and_hosted_server_security_i
nformation.pdf [Accessed 1 September 2015]. 
14 Health and Social Care Information Centre, 2010. Securing web infrastructure and supporting 
services: good practice guide.  http://systems.hscic.gov.uk/infogov/security/infrasec/gpg/ 
Securing-Web.pdf [Accessed 1 September 2015]. 
15 König HH, Ulshöfer A, Gregor M et al. Eur J Gastroenterol Hepatol 2002;14:1205–15. 
 
 
 
 
 
 
 
 
 
 
 
 
97 
© Healthcare Quality Improvement Partnership 2015 
 
 
Royal College of Physicians 
11 St Andrews Place 
Regent’s Park 
London NW1 4LE 
Inflammatory bowel disease programme:  
Clinical Effectiveness and Evaluation Unit 
Tel: +44 20 3075 1565 / 1566 
Email: ibd.audit@rcplondon.ac.uk 
www.rcplondon.ac.uk/ibd 
 
 
